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Introduction: 
 
The association between HIV and renal dysfunction is well documented in the 
HIV literature (Wyatt & Klotman 2006, Gupta et al. 2005 as cited by Mocroft et al. 
2007).  A syndemic relationship can exist between these two serious health 
conditions (Singer 2009).  While adherence to HIV medications is important, it 
can be difficult for a person who suffers from co-morbidity. In this thesis I 
examine possible barriers to adherence for HIV+ patients placed on renal dosing 
regimens.  The data for this research came from a larger psychological study on 
medication adherence.  Of the 590 patients in the study, 12 patients had their 
HIV medications changed to a renal dosed regimen.  All 12 patients suffered 
from renal toxicity from the ARV medication, Tenofovir.  The purpose of this 
thesis is to identify whether there are specific barriers to adherence that the 
patients on renal dosing identified and those on normal dosing schedules did not.  
The hypothesis of this thesis is that the switch to a renal dosed regimen will 
increase the barriers and difficulties patients have in adhering to their ARV 
medications. 
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This thesis begins with an examination of the literature on HIV and renal 
dysfunction, paying special attention to renal failure due to nephrotoxicity.  
Nephrotoxicity is the toxic effect that some medications have on the kidneys.  
Then, this thesis looks at participants’ responses to a survey that measured ARV 
medication adherence.  From this data, this thesis analyzes and discusses 
findings to determine if any trends exist between specific groups of participants.  
 
The data for this thesis came from a longitudinal, psychological investigation of 
barriers to adherence for ARV medications, called the LifeWindows Project 
(Fisher et al. 2011).  The research project ran from March 2006 to March 2008 at 
five HIV clinics located in the state of Connecticut.  Participants could only 
participate if they were patients of the clinic. Patients participated in the study for 
18 months and could complete a survey only once per month.     
 
I worked on this study as a research assistant.  While I was not involved in the 
design of the study, my duties included the retention of participants and 
maintenance of participant information.  During the study, I noticed that some 
patients had their medication regimens changed from taking the medications 
every day, to only taking the medications once or twice a week.  This was 
strange because ARV regimens require patients to take the medications 
everyday in order to be effective.  After investigating this occurrence the team 
found the medication, Viread, caused kidney problems in some of the patients.  
With the kidneys unable to function, these patients needed to undergo dialysis 
treatments.  Due to the way the body excreted the medication from the kidneys, 
the patients had to lower their ARV intake or the medication would become toxic. 
 
At the onset of the study, the medical community was unaware about the side 
effects incurred from prolonged use of Viread, which includes nephrotoxicity.  
Since that time, around 2% of the HIV population in the United States suffer from 
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this adverse reaction (Hamzah & Post 2009).  There is still more to learn about 
this issue, especially if other medications can cause nephrotoxicity. 
 
Renal dosing is a strategy a provider utilizes when a particular medication 
causes nephrotoxicity.  The provider lessens the number of prescribed doses in 
order to minimize medication toxicity in the patient.  This thesis examines the 
barriers to adherence for these participants by examining their responses on 
demographics and barriers to adherence.  Due to the small sample size this 
thesis cannot represent the greater HIV population.  Instead, this thesis intends 
to highlight areas that should be further investigated and tested.  Learning about 
the barriers that these participants faced can help future researchers focus their 
efforts in addressing barriers to adherence for HIV+ patients placed on renal 
dosing.   
 
Background on HIV and ARVs  
 
History of HIV: 
In the early 1980s, the human population became acutely aware of HIV.  The 
virus quickly spread worldwide, and this serious health problem became a global 
pandemic.  To date, the virus has infected over 33 million people worldwide 
(WHO: Global Summary of the HIV/AIDS epidemic, December 2008).  Like many 
diseases, the virus has affected developing nations the hardest.  However, HIV is 
still a serious problem in developed nations like the United States.  To date, HIV 
claimed the lives of over half a million Americans, disproportionately affecting 
poor and minority populations (AVERT: HIV and AIDS statistic summary). 
 
HIV is among the deadliest of diseases because the virus enters a host and 
attacks the CD4-cells in the body.  These cells are integral in the maintenance of 
a healthy immune system.  The CD4-cells combat infections and foreign 
organisms that enter the body.  The virus can alter the genetic coding of the 
CD4-cells, forcing them to replicate versions of the virus instead of creating more 
! %!
CD4-cells.  Over time the virus destroys the CD4-cell.  With a low number of 
CD4-cells in the body the host cannot fight off infections and becomes vulnerable 
to opportunistic infections and diseases. 
 
In the beginning of the HIV epidemic, HIV+ patients viewed infection as a death 
sentence because providers lacked medications to combat the virus.  This led to 
compromised immune systems for the patients.  Scientists searched for ways to 
combat HIV for years before they found an effective pharmaceutical combination 
-- the highly active antiretroviral therapy (HAART) -- that transformed AIDS from 
a death sentence to a chronic disease (Kak et al. 2000).   
 
Yet, the first ARV medication was not available until 1987, with the introduction of 
AZT, the first FDA approved medication, for the treatment of HIV (FDA: HIV/AIDS 
Historical Timeline).  Since then, newer and more effective medications are used 
to fight the virus.  In 1996, the medical community started to combine aggressive 
ARVs into medication regimens, giving rise to HAART (Moore et al. 2005).  With 
the effectiveness of the new medications and medication regimens, mortality 
rates dropped as people lived with HIV infection (Hooshyar et al. 2007).  
Although HAART is effective in battling HIV and keeping the individual alive, 
there is no cure for HIV.  The medications do not destroy the virus.  Rather, they 
keep the virus at bay by either preventing it from entering the CD4-cells or by 
preventing its replication.  
 
Adherence to Medication: 
Since HAART cannot destroy the virus, an HIV+ patient is infected for life.  The 
patient must take the medication every day in order to keep the virus from 
destroying the CD4-cells and replicating itself.  The virus can mutate when a 
patient misses doses of his/her medication.  HIV, as a type of RNA virus, 
produces high yields over short periods of times.  This high replication rate 
greatly increases the rate at which mutations occur.  HIV can rapidly respond to 
new challenges and environments, such as a missed dose of an ARV medication 
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(Domingo & Holland 1997).  If any of these new mutated versions of the virus 
become immune to the medication, resistant strains of the virus will make 
existing medications ineffective.  Such drug resistance renders the particular 
medication the patient took no longer effective in stopping HIV replication.  If the 
patient passes the mutated virus to another person, the newly infected person 
will contract a drug resistant strain, making that particular medication ineffective 
for both parties (Rintamakami et al. 2006, Fogarty et al. 2002). 
 
Thus, HIV+ patients must adhere to their medication regimen in order for the 
treatment to be effective.  Poor adherence is the number one cause of treatment 
failure for chronic diseases, especially HIV (Cressey & Lallemant 2007).  A 95% 
adherence rate is necessary to maintain medication efficacy and prevent the 
virus from developing resistance to the medication (Bautista-Arredondo et al. 
2010). 
 
Since adherence is of the utmost importance, health care providers should be 
involved in their patients’ care.  The providers must also ensure that their patients 
can adhere to medication regimens before prescribing HAART by observing the 
patients’ medication-taking behaviors (Hawkins 2010).  Adherence to HAART is 
the determining factor in whether or not the therapy will be effective (Barfod et al. 
2006).  Unfortunately there is no way for doctors to determine which of their 
patients will not adhere to HAART.  Therefore, providers must understand the 
barriers that cause their patients to be noncompliant, and identify and address 
these barriers so that patients can adhere to their medications (Fogarty et al. 
2002, Bangsberg et al. 2001). 
 
Barriers to Adherence:  
Before providers can understand the barriers to adherence they first need to 
understand the process of living with HIV and how barriers develop.  Some of 
these factors are external and lie outside of the patient’s control.  Many of these 
external factors develop out of economic, social, and political issues (Bautista-
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Arredondo et al. 2010).  The development of these factors is a result of HIV’s 
concentration among marginalized populations such as the poor, under-
educated, intravenous drug users (IDUs), people of color, and prisoners.  These 
groups also suffer from negative social stigma, which denies them economic 
gains and political control to address issues in their lives (Rintamakami et al. 
2006).  Members of stigmatized groups have less access to resources and may 
have a harder time obtaining medications to adhere to.  Many of these patients 
lack the social support structures necessary to counteract these factors 
(Maskovsky 2005, Hill et al. 2003).  To help these patients adhere to their 
medications, researchers, doctors, and public health officials designed numerous 
interventions to address these barriers and improve adherence. 
 
Other external factors that affect medication adherence lie not with society but 
with the provider.  At the time that the data for this thesis was collected, all but 
one of the HAART regimens included multiple HIV medications.  No single 
regimen works for every patient.  Sometimes the doctor does not prescribe an 
effective regimen or the correct dosing because medications react differently in 
different people (Cressey & Lallemant 2007).  The doctor may have to try several 
different regimens in order to find one that will work for the patient.  Each time a 
change is made in a medication regimen, it increases the difficulty for the patient 
to adhere to the regimen (Vrijens & Urquhart 2005).   
 
Adherence is also affected by the relationship between the patients and their 
providers. Patients that trust their doctor, and the prescribed therapy, are more 
likely to be adherent (Barfod et al. 2006, Remien et al. 2003).  It is not 
uncommon for patients to keep information, such as their adherence, from their 
providers (Hill et al. 2003).  Health care providers need to gain the trust of their 
patients when prescribing medications.  It is vital that providers take a patient-
centered approach to caring for their patients (Stein 2009).  Even successful 
patient-provider relationships can dissipate over time (Hunt et al. 1989).      
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While there are many external factors that the patient does not have control over 
there are internal factors that the patient can control.  These internal factors are 
associated with the beliefs a patient has, the behaviors a patient exhibits, and the 
actions a patient takes.  These internal factors can create adherence barriers that 
can affect patients, regardless of their socio-economic status.  Doctors, 
researchers, and patients must identify and overcome these barriers for viral 
suppression to occur (Chesney 2000).  Interventions to increase patient 
adherence developed from a better understanding of these barriers (Berg et al. 
2004, Bogart et al. 2010).  Some of these interventions use discussion and 
education to change a patient’s beliefs and behaviors (Mills et al. 2006).  The 
provider can work with the patient and educate him/her on the medications and 
on adherence techniques (Roberts 2000).  Researchers also developed 
interventions that patients can use at home (Jerant et al. 2005).   
 
Even after a provider identifies the internal and external factors that affect 
adherence, he/she still needs to understand the complex barriers that a patient 
lives with.  These barriers are broad and deal with a wide range of aspects of 
living with HIV (Chesney 2000).  Each patient is unique and has different 
experiences, so it is difficult to determine if a given factor will cause a barrier for a 
given patient.  Researchers found four factors that are salient predictors of 
noncompliance, which include the patient’s living situation, psychological health, 
access to medications, and history of substance abuse (Fisher et al. 2006).  
These factors comprise the IMB model of adherence to HAART. If a patient has 
difficulties with any of these factors, barriers to adherence usually follow.  This 
model is linked with the individual’s health outcomes, which include his/her 
physical health, quality of life, and current HIV status (Fisher et al. 2006). 
 
Increasing Adherence: The IMB Model:  
While some patients have stable living situations and access to medications, and 
lack psychological issues, and substance abuse problems, these patients can 
still possess barriers to adherence.  Trying to identify the barriers to adherence 
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for these patients is extremely difficult.  One tool that is effective is the 
Information, Motivation, and Belief (IMB) model of adherence (Fisher et al. 2006).  
By using this model, providers can better understand, predict, and promote 
adherence with their patients.  With the IMB model the providers can examine 
the information patients possess about HIV and their medications; the 
motivations and beliefs patients have about the virus, their medications, and what 
it is like to live with HIV; and the behavioral skills the patients possess and their 
ability to adhere to their medications.  When patients are “well informed, 
motivated to act, and possess behavioral skills required to act, adherence can be 
maintained” (Fisher et al. 2006).  It is important to take the concept of culture into 
account when looking at the factors that affect adherence.  Cultural practices and 
beliefs will vary, which can change the understanding of these factors.  When 
utilizing the IMB model of adherence one must understand the culture to 
determine the model-based elements of the IMB model that are appropriate 
(Fisher et al. 2006).  The IMB model of adherence helps providers identify 
adherence barriers for patients who may not have any of the four major factors 
associated with non-adherence as discussed above. 
 
When using the IMB model it is important for providers to remember that life with 
HIV is not uniform for all people.  Different groups of people will face different 
issues, and as a result may have different barriers, and the barriers associated 
with one group may not affect another group.  For example, the barriers that 
affect IDUs are quite different from those that affect other groups (Krusi et al. 
2010).  When researching medication adherence providers and researchers 
should always look for other factors that can affect adherence.  To do so the 
providers and researchers need to comprehend what life is like for the patients 
and understand the patients’ values, judgments, habits, and behaviors (Max & 
Sherer 2000).   
 
On the surface, adherence appears to be cut and dry.  A provider wants to know 
if his/her patient took the medications as prescribed.  When a patient is not 
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adherent to his/her medication the medical community considers the patient to be 
noncompliant. The language of compliance shows the power dynamic that the 
provider has over the patient (Trostle 1988).  The provider is the holder of 
knowledge and the patient is subject to the rituals of the healthcare setting 
(Papen 2010).  This noncompliant point of view is only from the doctor’s and is 
devoid of the patient’s perspectives.  Noncompliance can make it appear that the 
patient does not take care of himself/herself, and that the patient lacks agency.  
Yet, there are things that the patient can do for his/her health that do not include 
HAART, which a provider may not take into account.  The patient can attempt to 
manage HIV in ways that are not assessed by the clinician (Trostle 1988).  
Similarly, the language of noncompliance can place blame on the patient and the 
provider may assume that the patient ‘disobeyed’ his/her instructions (Rousse 
2010).  Yet, the patient could be a victim of structural violence due to 
discrimination and economic inequality (Scheper-Hughes & Bourgois 2004 as 
cited by Rousse 2010, and Chapman & Berggren 2005).   Thus, many in the 
medical community use the language of adherence, with the hope that the power 
differences will not be present in the language.  “The shift from compliance to 
adherence demonstrates a growing awareness of power relations in doctor-
patient interactions and of the frequently cited distrust in institutions such as 
biomedicine” (Leibing 2010). 
 
One strategy that providers can use to better understand patients is to become 
aware of the cultural aspects of their patients’ lives.  The hope is that by 
understanding their patients; providers can connect to their patients (Stein 2009).  
Providers attempt to do this through cultural competency.   Cultural competency  
 
refer[s] to a body of knowledge, skills, attitudes, and behavior in which physicians 
ought to be trained if they are to deliver “sensitive,” “empathetic,” “humanistic” 
care that is “respectful” of patients, involves effective “patient-centered 
communication,” and responds to patients’ “psychosocial issues and needs” (Fox 
2005). 
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Unfortunately, many providers and medical schools view cultural competency as 
a list of “dos and don’ts” that correlate with a particular population (Betancourt 
2004).  This view of cultural competency is wrong because “the idea of isolated 
societies with shared cultural meanings would be rejected by anthropologists, 
today, since it leads to dangerous stereotyping (Kleinman & Benson 2006).  
Understanding a cultural belief is important but a “one-size fits all” approach is 
ineffective.  For example, many providers believe that patients with strong 
religious beliefs are more likely to be adherent.  Yet, some patients believe that a 
higher power gave HIV to them and these patients accept their fate and do not 
take their ARVs (Kremer et al. 2009).  In addition, many providers do not 
understand the self-reflexive nature that cultural competency requires.  Many 
view the biomedical system as devoid of culture (Fox 2005, Kleinman & Benson 
2006, and Taylor 2003).  Without understanding how the providers and their 
medical culture affect the patients, the providers cannot truly understand the 
patients.   
 
Thus, a useful method to understand a patient’s perspective is the use of an 
explanatory model approach (Kleinman & Benson 2006).  An explanatory model 
allows the patient to make sense of his/her illness and how he/she experiences 
that illness (Kleinman 1978, and Kleinman 1988).  The provider can 
communicate with the patient using the language of the patient and the provider 
can understanding the patient’s own illness narrative (Kleinman 1988, and 
Kleinman & Benson 2006).  Previous research shows that the use of patient 
illness narratives can be effective in understanding aspects of HIV medication 
adherence and in increasing adherence itself (Wrubel et al. 2011, Scott 2009, 
and Sankar et al. 2011).  Some of the patients’ definitions of adherence can be 
quite different than their providers.  For example, a patient can change the 
dosing of his/her ARV without consulting his/her clinician.  While a provider would 
consider this patient noncompliant, this type of patient may feel that he/she was 
adherent to the medication because he/she still took them (Hill et al. 2003).  
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Understanding the explanatory models of patients includes aspects such as 
whether or not the patients believe in the efficacy of HAART and if they 
understand how the medications work (Chesney 2003).  Providers also need to 
comprehend the definitions and language of their patients.  Simply recalling 
information does not guarantee adherence, especially when that information is 
not understood (Hunt et al. 1989).  Living with HIV is a personally experienced 
illness in which the meaning of the disease can be different for each patient 
(Scott 2009).  For example, some patients view their status as a form of 
punishment for past behaviors (Scott 2009).  Some patients perceive their bodies 
as frail while others view their bodies as strong and able to “withstand” HIV 
without medications (Hill et al. 2003).  Other patients can become confused in 
regards to the importance of adherence.  Adding to this confusion, sometimes 
providers place patients on structured treatment interruptions (STIs), after 
harping on the importance of adherence for months.  This conflicting information 
can confuse patients about the importance of adherence (Adam et al. 2003).       
 
Adhering to any type of medication, not just an ARV, is difficult and barriers often 
develop.  Additionally, therapies for chronic conditions are harder to adhere to 
over time.  Patients who suffer from chronic conditions, like HIV, have to make 
their medications a part of their daily lives and adhere to the treatment for the 
rest of their lives (Polaschek 2003).  These patients may need assistance in 
increasing their personal care goals and self-efficacy to manage their disease.  
This means that patients must be educated about their health issues and 
empowered to take control of their medications (Jerant et al. 2005).   
 
Studies show that it is difficult for people to adhere to simple regimens that only 
require one pill to be taken once a day (Osterberg & Blaschke 2005).  Unlike 
many other regimens, HIV medication regimens have a high pill burden.  Most of 
the HIV medication regimens prescribed to the patients in this study required the 
patients to take two to three different medications.  Many of these regimens 
consisted of multiple pills that were prescribed at different times of the day.  
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Although there are improvements in simplifying these regimens, HIV medications 
continue to be one of the most difficult regimens for patients to adhere to 
(Osterberg & Blaschke 2005).  
 
While a number of internal and external factors that create barriers to adherence 
exist, ultimately it is the tolerability of the medications that plays the most 
significant role in determining adherence (Hawkins 2010).  If a patient cannot 
tolerate the medication and its adverse effects, it is likely that the patient will have 
difficulty adhering to the therapy. 
 
Side Effects and Medication Toxicity: 
All medications have some type of adverse effects or side effects, which are the 
unintended physiological reactions a person has to a given medication.  Some 
side effects are mild and may dissipate after taking the medication for a few 
weeks.  Other side effects can persist for as long as the patient is taking the 
medication (Remien et al. 2003).  The experience of side effects is an 
individualized phenomenon.  There are varying degrees of these effects and 
patients may conceptualize the side effects differently.  Scientifically, side effects 
are the secondary reactions to the medication, while the primary reaction treats 
the intended illness.  Yet, a patient’s beliefs about side effects can be culturally 
based.  Vomiting and diarrhea, while considered side effects to the medical 
community, some cultures view as part of the natural healing process (Etkin 
1992).         
 
Unfortunately, it is the long-term side effects that many HIV+ patients suffer.  
Some of these side effects are so serious that they can make patients feel sicker 
than the virus alone does.  Patients must determine how they feel about their 
medications and if they are to manage the side effects.  Some patients learn to 
deal with the side effects (Shoemaker & Ramalho de Oliveira 2008).  While 
others refuse to take a medication that makes them feel sicker (Adam et al. 
2003), other patients feel that the medications take control over their lives 
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(Dolovich et al. 2008).  Some patients become complacent with the side effects 
because the side effects may kill them faster than the disease (Shoemaker & 
Ramalho de Oliveira 2008).  Understanding patients’ personal and cultural beliefs 
on side effects is important to aid in adherence because without this 
understanding, providers may be unable to conceptualize what it is like for their 
patients to experience these side effects.  
 
One of the most serious types of side effects is medication toxicity (Chesney 
2003).  This occurs when a medication is too strong for the body and becomes 
toxic, causing the patient to develop additional, and sometimes deadly, health 
problems. The patient is dependent upon the medication to fight the virus to 
maintain his/her health.  Because of the medication’s toxicity, if the patient 
continues to take the medication everyday, he/she will become sicker.  
Medication toxicity typically does not dissipate over time (Clifford et al. 2009).  
While adherence to ARVs is difficult, a HIV+ patient who develops toxic reactions 
from his/her medication now suffers from multiple life-threatening conditions. 
 
Little is known about the long-term effects that HAART has on the aging body 
because HIV medications are relatively new (Max & Sherer 2000, McPhail & 
Robertson 2011, Palmisano & Villa 2011).  Unless a cure is found, HIV+ patients 
will rely on these medications for the rest of their lives.  It is difficult to predict 
what types of reactions their bodies will have to these medications when taken 
for a prolonged period of time.  Even less is known about the long-term effects 
caused by ARV toxicity because clinical studies are typically not long enough to 
capture this information (Hawkins 2010).  Sadly, many believe that investing time 
and money in understand the long-term effects of the current HIV medications is 
not cost-effective since, due to the highly mutative nature of the virus, patients 
are in constant need of new medications to repress viral replication.   
 
Medication toxicity is a unique factor for studying adherence.  Every patient’s 
body is different, and because of pharmacogenetic variability (biological 
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individualism) there is no way to predict how a patient will respond to a 
medication or what the side effects will be (Cressey & Lallemant 2007).  While 
guidelines for the prescribing and dosing of these medications exist, ultimately, a 
provider needs to know his/her patients and watch how each individual reacts to 
the medications.  To do this, a provider must develop rapport with his/her 
patients.  Trust and honesty are necessary in the patient-provider relationship.  
The doctor needs to ask tough questions that deal with the personal factors that 
affect adherence like alcohol and drug use, physiological and emotional health, 
and personal feelings about health and therapy.  The patient also needs to feel 
comfortable answering these questions truthfully.  Only with complete honesty 
will the doctor understand how the medication affects the patient and gauge what 
types of adherence barriers need to be addressed. 
  
It can be difficult for patients and providers to have these necessary 
conversations.  The social, physical, emotional, and psychological aspects of 
living with HIV are extremely personal, and such conversations delve into the 
intimate parts of peoples’ lives.  Moreover, studies show that such conversations 
between patients and providers are typically awkward (Barfod et al. 2006).  It can 
be hard for patients to open up and be honest with their doctors because the 
doctors are the ones with the power in the relationship (Osterberg & Blaschke 
2005).  The clinicians control whether or not the patients can receive therapy, 
and many patients just want to tell the doctors what the doctors want to hear 
(Osterberg & Blaschke 2005).  It is not uncommon for doctors to judge their 
patients (Trostle 1988), and not address the social stigma associated with having 
HIV and this can emotionally affect patients (Rintamakami et al. 2006). 
 
Renal Toxicity: 
Toxicity is a serious concern when using HAART, and some forms of medication 
toxicity are fatal.  One of the newest forms of HAART associated with toxicity 
involves particular HIV medications that affect a patient’s kidneys.  In fact, 
regardless of renal toxicity, a correlation between HIV and kidney problems 
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already exists.  Due to the nature of HIV, and the way it compromises the 
immune system, many HIV+ patients already have renal problems (Post et al. 
2008).  Kidney disease is the third leading cause of death in HIV+ patients 
(Santos, Seguro, & Andrade 2010), and 30% of HIV+ patients have abnormal 
kidney function (Singer 2009).  In fact, when renal problems develop, over a third 
of the time, US doctors immediately check to see if the patient contracted HIV 
(Rao 2001).  The virus not only infects CD4-cells but also compromises cells in 
the kidneys causing renal problems and can ultimately cause renal failure.   
 
Renal toxicity is a major threat to patients’ health, and some medications 
(including several HIV medications) are nephrotoxic.  By taking these 
medications patients may experience a side effect in which their medications 
causes additional problems with the kidneys and may ultimately cause kidney 
failure, which can be fatal (Roling et al. 2006 and Daugas, Rougier, & Hill 2005).  
Due to the limited number of HIV medications, pharmacogenetic variability, and 
drug-resistant strains of HIV, patients require these medications even though the 
medications may eventually harm the patients.  Statistically, most patients never 
develop these fatal renal problems, so their best chance at survival is taking 
these potentially harmful medications (Post et al. 2008).  HIV+ patients that 
develop renal side effects from their HIV medications must undergo dialysis 
treatment in order to continue their necessary ARV treatments.   
  
Some of the nephrotoxic medications are excreted through the kidneys.  If left in 
the body these medications would become even more toxic and would kill the 
patient.  The provider and patient face a puzzling dilemma.  If the patient were to 
stop taking the medication, the virus would mutate, rendering the medication 
ineffective and HIV would replicate throughout the bloodstream eventually 
compromising the patient’s immune system, leading to death.  Yet, if the patient 
continues to take his/her medication every day, as prescribed, the kidneys could 
not flush the medication out of the body thus making the medication toxic, killing 
the patient.  Due to this predicament, doctors, pharmacists, drug companies, and 
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researchers advise providers to change the dosage of the medication and follow 
specific guidelines called renal dosing. 
 
Renal dosing itself is not new and is used on a variety of medications.  Since the 
kidneys cannot excrete the medication out of the body, placing more medication 
in the body becomes dangerous.  The doctor changes how often the patient 
takes the medication so that the medication can still be effective, while not 
becoming overly toxic.  The protocol for renal dosing is different for each 
medication, but for most of the HIV medications that are still used today, the 
doctor instructs the patient to take the medication only after dialysis treatment, 
which is typically once or twice a week.  By following this strategy, the body takes 
in the medication and that single dose will remain in the body to combat HIV until 
the next dialysis treatment.  The dialysis treatment removes the medication from 
the body; thus, another dose of the medication is needed.  While renal dosing is 
not perfect in combating the virus, pharmaceutical research show that it is 
effective in keeping HIV from destroying the patient’s immune system (Gilead: 
Pharmaceutical Manufacturer, Highlights of prescribing information).  
 
While providers utilized renal dosing strategies since the 1950s, the renal dosing 
of HIV medications is still relatively new in the medical world.  It was not until the 
early 2000s,that the medical community discovered the need for renal dosing in 
HAART.  Until a few years ago, all of the literature stated that HIV medications 
could only be effective if taken every day.  The addition of renal dosing greatly 
changed the way in which providers prescribe HAART.  Even with the number of 
adherence interventions, noncompliance with HIV medications continues to be a 
major issue for patients placed on renal dosing (Santos, Seguro, & Andrade 
2010).  Although mortality rates for HIV+ patients decreased over the years, 
mortality rates for HIV+ patients with renal problems remains high (Rodriguez 
2003).   
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Tenofovir and Toxicity: 
Over the years the medical community identified various nephrotoxic medications 
and  replaced many with newer and safer medications.  This thesis focuses on 
one recently identified nephrotoxic ARV called Tenofovir, also known by its brand 
name: Viread (Bruggeman, Bark, & Kalayjan 2009, Kearney et al. 2004).  
Tenofovir is an HIV medication in the class of nucleotide reverse transcriptase 
inhibitors (NRTIs).  NRTIs work by preventing HIV from changing the genetic 
coding of CD-4 cells, stopping the cell from making new copies of the virus.  
Tenofovir is a newer medication and the FDA approved it in 2001 (FDA: 
Antiretroviral drugs used in the treatment of HIV infection).  The medication is a 
successor to previous medications that patients found less tolerable.  A single 
dose of Tenofovir, once a day, is effective to stop HIV replication, making it a 
very popular medication in drug regimens.  Tenofovir is also an active ingredient 
in many of the combination medications that combine multiple HIV medications 
into one pill. 
 
While Tenofovir is extremely effective in combating HIV, studies show that the 
medication can cause renal problems (Gallant & Moore 2009, Karras et al. 2003, 
Schaaf et al. 2003, Zimmerman et al. 2006).  The pharmacogenetic variability of 
the medication is diverse.  Patients react differently to the medication and there is 
no way to predict if renal toxicity will occur.  After years of testing and years on 
the market, the initial data did not show any correlation between the medication 
and renal problems.  As the years passed studies began to reveal that Tenofovir 
caused renal problems.  An explanation for the lack of initial data is that 
prolonged use of the medication increases the likelihood of renal issues (Rosso, 
Ginocchio, & Bassetti 2008, Coca & Perazella 2002).  While there is some 
literature on these adverse events, the literature is still scarce.  At the present 
time only 2% of the HIV population in the United States suffer from renal 
problems caused by Tenofovir (Hamzah & Post 2009).  While this may not 
appear to be a major medical concern, some researchers and doctors believe 
that the incidence of renal dosing will greatly increase in the next few years 
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(Wanner, Tyndall, & Walker 2009).  The popularity of the medication (Shepp, 
Curtis, & Rooney 2007), combined with prolonged use, may result in an increase 
of renal problems. 
 
With both limited kidney function and compromised immune systems, it is 
extremely important that HIV+ patients with renal complications adhere to their 
medication regimen even while they are on renal dosing.  If the virus is 
uncontrollable it can cause serious health problems for patients with a 
compromised renal system.  Even with the adverse problems associated with the 
medication, HAART therapy is still effective in patients undergoing dialysis 
(Ahuja, Borucki, & Grady 2000).  While adherence for this group of people is 
extremely important, almost no research is conducted with them.  This is 
probably because renal dosing of HIV medications is still new to the field.  This 
makes renal dosing a factor in adherence that deserves further research.  
Understanding drug toxicity and the barriers it presents is important in 
determining whether patients will adhere to their medication regimens (Szczech 
et al. 2002). 
 
While adherence is an issue for all HIV+ patients, those on renal dosing have 
additional issues that need addressing.  There is no set standard of renal dosing 
for providers to follow.  While the drug companies supply guidelines, patients are 
unique and the medication may react differently with each patient, making the 
dosing dependent on the level of renal problems each patient has (Kearney et al. 
2004).  This means that providers must be attentive to patients who have renal 
issues and take these renal problems into account when prescribing medications 
(Papaioannou et al. 2000).   
 
Due to the large number of patients it can be difficult for providers to keep up to 
date on all of their patients.  Unfortunately, some medications are incorrectly 
prescribed to patients (Rodriguez 2003), and some studies suggest that many of 
the nephrotoxic medications are overprescribed (Papaioannou et al. 2000).  In 
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addition,  some HIV+ patients do not receive adequate dosing of their 
medications to suppress the virus (Szczech et al. 2003).  This variability in the 
recommended dosing makes it difficult for providers to prescribe the right dosing 
for their patients.  Ultimately, prescribing can become a trial and error method.  In 
situations like this, good rapport with patients is again vital for the patient-
provider relationship. Doctors need to understand patients’ lived experiences and 
the patients need to trust their doctors.  Without a good working rapport, this is 
nearly impossible (Tourret et al. 2007).   
 
There is an added burden on the patient-provider relationship for renal dosed 
patients.  Two of the groups that renal dosing affects the most are African 
Americans (AA) and Intravenous Drug Users (IDUs), who often have poor 
rapport with providers (Bogart et al. 2010).  This places even more demand on 
providers to strengthen their relationships with these patients because incorrect 
dosing can lead to increased toxicity and adverse events, which, in turn, can 
decrease adherence and cause drug resistance (Willig et al. 2007). 
 
Even when providers find the correct dosing, human error can still occur.  In a 
number of hospital studies, doctors and nurses made errors in the dosing of this 
medication.  The doctors and nurses administered suboptimal therapy (Ahuja, 
Grady, & Khan 2002), which led to complications that resulted in decreased 
survival rates (Tourret et al. 2007).  Patients not receiving the correct dose of the 
medication was the cause of some these errors, but patients not receiving the 
medications at the correct time was the cause of most of the errors (Tourret et al. 
2007).  For patients on renal dosing, there is a specific time frame within which 
the medications should be administered, and many of the hospital workers did 
not give the medications to the patients in accordance with these guidelines 
(Tourret et al. 2007). 
 
If patients receive suboptimal therapy in the hospitals, where trained 
professionals administer the medications, then adherence in the home, where 
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patients take their own medications, must be a high priority and should be 
studied more.  Many renal dosing patients travel to a dialysis center.  Since the 
patients travel, the patients need to remember to bring their medications with 
them and take the medications at the proper time.  Although there are health 
care professionals at the dialysis centers, these professionals are not the HIV 
care providers.  Thus, the HIV clinicians do not know whether their patients are 
taking the medications at the proper times.   
 
HIV medication regimens have a high pill burden and it is difficult for patients to 
adhere to them (Wensing, van Maarseveen, & Nijhuis 2010).  HIV regimens 
usually include multiple medications that must be taken every day.  Patients on 
renal dosing have a higher pill burden than other HIV+ patients.  Renal dosing 
patients must remember to take some of their medications every day as originally 
prescribed, and the renal dosing medications only after dialysis.  It can be 
challenging for HIV+ patients to remember to take their pills every day.  Changing 
patients’ regimens to renal dosing greatly increases the chances of 
noncompliance because patients must remember to take some of their 
medications everyday and other medications only a few times a week.   This is 
difficult for patients who were on their medications for a prolonged period of time 
and developed pill-taking habits.   
 
Renal dosing patients, like many other HIV+ patients, suffer from comorbidity, the 
presence of two or more diseases.  Managing one disease is difficult, but 
managing multiple diseases is extremely problematic (Bayliss, Ellis, & Steiner 
2007).  Comorbidity in HIV+ patients increases the likelihood of opportunistic 
infections and a compromised immune system (Ahuja, Grady, & Khan 2002).  
Patients must adhere to therapy for all of their illnesses because if they are 
noncompliant with a therapy their health can deteriorate.  Patients who have 
multiple chronic conditions have increased health burdens.  By increasing 
patients’ self-efficacy and agency, providers can assist in the adherence to 
medication therapies. 
! #"!
 
While these factors affect a number of HIV+ patients with comorbidity, renal 
patients have additional factors.  Due to the unique dosing regimen of this group, 
and the pharmacogenetic variability of the medications, the medications may not 
be potent enough to be effective.  Even when patients are adherent to their 
regimen, there is no guarantee that the medications will be effective (Cressey & 
Lallemant 2007).  This can become frustrating for patients and the providers, and 
typically both find something or someone to blame (Maskovsky 2005).  In 
situations such as this the providers may place the blame on the patient, while 
the patients may place the blame on the therapies (Rousse 2010).  In scenarios 
such as this, the chances of adherence are greatly reduced because the rapport 
between provider and patient is lost (Seema et al. 2011, and Beck & Gordon 
2010). 
 
The therapies used to treat HIV+ patients on renal dosing are complicated and 
the adverse effects can cause additional health problems for the patient (Singer 
2009).  Adverse effects like drug toxicity greatly interfere with the daily routines of 
patients, which, in turn, can affect adherence (Remien et al. 2003).  Patients 
need to believe that the medications are helping them even when the side effects 
are detrimental to their health.  If patients believe the medications are hurting 
them, complications usually arise in adherence (Remien et al. 2003).   
 
Patients on renal dosing receive at least two types of therapy for their chronic 
conditions.  They receive HAART for their HIV and dialysis for their kidney 
problems.  It is hard for some patients to trust in either of their therapies because 
the therapies can become iatrogenic syndemic.  Iatrogenic syndemics occur 
when the healing therapies used to treat conditions in a comorbid patient cause 
adverse effects that make the disease not treated by the medication worse 
(Singer 2009).  For renal-affected HIV+ patients, taking nephrotoxic HIV 
medications stops HIV replication but causes kidney damage or failure.  Some 
studies show that dialysis treatments can make HIV replicate at a faster rate 
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(Ahuja, Grady, & Khan 2002).  Thus, undergoing dialysis treatments allows 
patients to excrete the toxic waste from their bodies but may cause faster virus 
replication.  Patients must adhere to both therapies for survival, yet each therapy 
can make the other condition worse.  This makes the patients even more reliant 
on the treatment, which in turn can cause the conditions to worsen.  
Noncompliance for those who are on ARV and dialysis treatments is common (as 
cited by Curtin, RB et al. 1999, Leggat, JE et al. 1998, and Kimmel, PL et al. 
1995 in Loghman-Adham 2003), and this cycle may make it worse. 
 
Review: 
In sum, adherence to an antiretroviral (ARV) medication regimen is necessary for 
seropositive individuals to survive.  Due to the vast number of factors and 
difficulties people experience from living with HIV, barriers to medication 
adherence develop.  Understanding these barriers and helping HIV+ people 
overcome them can greatly increase rates of adherence.  However, little 
research is conducted on the barriers to adherence for people living with HIV that 
providers place on a renal dosing ARV medication regimen.  In addition, this 
population experiences unique conditions in living with HIV.  This can result in 
specific barriers to adherence for population.  Thus, more research needs to be 
conducted on adherence and the barriers to adherence for this population. 
 
LifeWindows Project Background: 
 
The LifeWindows project (Fisher et al. 2011) is a psychological research study 
headed by Dr. Jeffrey Fisher, head of the University of Connecticut’s Center for 
Health, Intervention, and Prevention (CHIP).  I worked for Dr. Fisher as a 
researcher on this project.  The team developed the survey instrument and 
protocols for the study prior to my arrival.  My roles as a researcher included: the 
testing of the computer program, participant recruitment, participant retention, 
working with patients, running participants through the LifeWindows program, 
! #$!
and administrative duties.  Dr. Fisher and the research team gave consent for 
use of project data for this thesis.  
 
The team conducted the study at five HIV clinics located throughout the state of 
Connecticut.  PhDs, administrative and support staff, and an on site researcher 
for each of the HIV clinics comprised the LifeWindows Project team.  This was a 
voluntary study and all participants gave written, informed consent to participate 
in the research.  The Institutional Review Boards (IRB) at the University of 
Connecticut and at each of the HIV clinics approved this research.  
  
LifeWindows Computer Program: 
LifeWindows is an interactive computer based ARV adherence support 
intervention. The computer program worked with HIV+ patients based on the IMB 
model of adherence in order to assess patient adherence, identify barriers to 
adherence, and test the efficacy of specific adherence interventions.  
  
As previously discussed, the IMB model of adherence works on the premise that 
information, motivation, and behavioral skills are critical factors that affect 
adherence and those patients that possess these skills can apply them to their 
ARV regimen.  The IMB model also suggests that identifying the barriers to these 
skills and addressing them can increase patients’ adherence.  The study included 
both a control arm and an intervention arm.  Participants in both arms used the 
LifeWindows computer program, but only those patients in the intervention arm 
had exposure to the adherence interventions.   
 
The computer program consisted of several components.  The first component 
was a tutorial that explained basic computer usage and how to use the 
LifeWindows program.  Each time a patient entered the program Marcus, a 
virtual guide, greeted the participant, introduced him/her to LifeWindows and 
helped him/her navigate through the computer program. 
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After Marcus’s greeting, the patient completed a general assessment module.  
The first part of this module elicited background information and demographic 
characteristics (these survey questions are in Table 7 located in the Appendix) by 
allowing the patient to choose from a list of provided responses.  The patient 
completed the survey by using the mouse to click on the responses.  Due to the 
nature of these questions, the responses ranged from binomial (yes/no) 
responses (e.g., Are you currently taking a break from your HIV medications 
without talking to your healthcare provider?) to questions that provided over 20 
responses to choose from (e.g., In what year were you diagnosed with HIV?).   
Also, some of the questions asked for a single response while others asked for 
all responses that applied (e.g., How did you first get HIV?)  During the baseline 
session of LifeWindows the patient completed the entire survey.  On subsequent 
sessions the patient only responded to questions about things that could have 
changed since the last visit.  The patient could also to choose “Prefer not to 
answer” for all of the questions. 
 
The second part of the module was a survey of possible barriers to adherence 
(the survey questions are in Table 8 located in the Appendix).  Like the 
demographic survey, this part of the module showed the patient responses for 
each question.  Also like the previous survey, the number of responses was not 
uniform.  Many of the questions’ responses were Likert scales.  The survey 
looked for barriers to adherence based on the IMB model.  Thus, questions 
asked focused on the patient’s informational, motivational, and behavioral skills. 
The patient had the option to choose “Prefer not to answer” for all of the 
questions. 
 
The final portion of this module was an interactive survey to assess ARV 
adherence.  The module started with a section called the “Pill Picker.”  In this 
section the patient chose all of the HIV medications that he/she was prescribed.  
To help the patient choose the correct medications, the program showed pictures 
of each ARV medication.  The list included both brand and generic medications 
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that were in use during the time of the study.  Also the patient could sort the list 
by the medications’ name, size and shape, or function. 
 
Prior to the patient’s session of LifeWindows, the site researcher would examine 
the patient’s medical chart and update the program’s database with the current 
ARV medications.  During the “Pill Picker” section, if the patient failed to choose 
the correct medication or chose a medication that was not in the database, the 
program took the patient to the “Discrepancy” section.  In this section the 
computer showed the patient which medications were listed in the database and 
which medications he/she chose.  The patient then choose the medications that 
he/she believed he/she was on, which would override the discrepancy if 
necessary, but would create a report for the team to examine at a later time.  
When completed, or if no discrepancy existed, the system brought the patient to 
the adherence survey. 
 
The adherence survey asked the patient to report on his/her adherence over the 
last three days and over the last four weeks.  The system displayed a daily 
calendar for each of the ARV medications.  Then the program asked the patient 
to choose the times during the day and the number of pills prescribed for each 
HIV medication.  The program asked the patient to report whether he/she took 
each medication over the last three days and how many pills he/she took at that 
time.  The patient reported his/her adherence in the form of a percentage with 
0% signifying that he/she took no medications, to 100%, which signified that 
he/she took all medications as prescribed.  The computer asked the patient to 
report on each medication for the past three days and then for the past four 
weeks. 
 
This was the end of the program for those patients in the control arm of the 
experiment. The patients in the intervention arm went on to receive an adherence 
support component that had 20 different individually targeted intervention 
activities. The patients interacted and completed the activities on the computer.  
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The activities included things such as: an informational movie, asking experts 
specific questions, a computer game, receiving relevant information, and a 
variety of other activities (the listing and description of the intervention modules 
are in Table 9, located in Appendix).  The computer program kept a record of the 
survey questions that positively identified possible barriers to adherence from the 
general assessment.  Each of these questions linked to a particular adherence 
strategy (a list of these strategies is in Table 10 located in the appendix).   After 
completing the general assessment the patients in the intervention arm chose 
from a list of adherence strategies that they could work on while in LifeWindows.  
The strategies linked to the survey questions that identified a possible barrier to 
adherence.  After choosing a strategy, the patients chose which interventions 
they wanted to complete.  The patients selected the intervention they wanted to 
work on and engaged in the activity.  Each of these interventions addressed 
specific adherence strategies.  The purposes of these interventions were to 
increase patients’ information about HIV and HAART, increase patients’ 
motivation about taking medication, and change patients’ behavioral skills in 
taking medications.  Table 11 (located in the appendix) shows which strategies 
and interventions linked to each question. 
  
After completing the interactive activity the patient went to a goal selection 
module.  In this module the patient chose an adherence related goal.  The 
program presented some already prepared goals on the screen.  These goals 
focused on the patient’s self-identified barriers to adherence and the intervention 
the patient completed.  The patient could also create a personal goal.  The 
system printed the goal and presented it to the patient.  On subsequent visits 
Marcus asked the patient about his/her progress on the goal.   
 
The LifeWindows session concluded with a farewell message from Marcus, 
reminding the patient to return to LifeWindows during the next doctor visit.  On 
the final LifeWindows session, or exit survey, Marcus thanked the patient for 
his/her help in the study. 
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LifeWindows Survey Questions: 
 
As previously discussed, the LifeWindows computer program consisted of three 
different computer delivered surveys: demographic information, adherence 
barrier identification, and adherence to HAART medication regimen.  The data 
used in this thesis focuses mainly on the adherence barrier identification survey. 
The LifeWindows research team developed these questions to identify possible 
barriers to adherence that affected participants in the study.  Nearly all of the 
responses to the questions were Likert scales.  Each time the patients 
participated in a LifeWindows session, the program asked the same 45 
questions.  Of the 45 questions, only 34 linked to an adherence strategy.  The 
remaining questions still identified barriers to adherence, but did not affect the 
LifeWindows session.   
 
Barriers Identified in LifeWindows: 
The questions, responses, strategies, and interventions identified in this thesis all 
came directly from the LifeWindows program, and the LifeWindows team 
developed them using the IMB model of adherence, research from previous 
studies, and consultations with HIV clinicians.  While the general assessment 
identified barriers to adherence, the research team did not name each specific 
barrier.  For this thesis I created the names for the barriers to adherence based 
on each survey question and its linked adherence strategy.  The full list of 
barriers addressed through the strategies and interventions are in Table 12 
located in the appendix. 
 
The LifeWindows program identified a total of 37 barriers, based on the IMB 
model of adherence.  Since there were 45 survey questions and 34 adherence 
strategies, some of the barriers correlated with multiple questions.  The research 
team developed these questions because they believed that barriers could exist 
for people in a variety of ways.  Developing the questions in this manner allowed 
! #)!
the team to identify more barriers to adherence, and with these barriers the 
program routed the patient to the appropriate intervention. 
 
LifeWindows Results: 
The LifeWindows study tested the hypothesis that those patients exposed to the 
interventions would have greater adherence over time than those patients in the 
control arm, because the interventions better addressed the barriers to 
adherence than the patients’ previous exposure.  The purpose of this study was 
to test the hypothesis and, if proven, to determine which interventions most 
improved patients’ adherence.  The study found that the intervention significantly 
improved adherence (Fisher et al. 2011).  
 
Participants for this Thesis: 
 
The team recruited 590 participants for the LifeWindows study.  The criteria for 
inclusion into the study were that each participant had to be: HIV+, a patient of 
the clinic, 18 years of age or older, on ARV therapy at baseline, and competent in 
the English language at a fourth grade reading level.  Recruitment occurred at all 
five of the HIV clinics.  Each clinic had affiliations with its own hospital and its 
location was within or next to the given hospital.  Four of the five hospitals were 
cities in poor neighborhoods in the state.  Most of the participants were minorities 
from a lower socio-economic status.    
 
Nurses, physician assistants, and doctors staffed the clinics.  The number of 
times patients frequented the clinic depended on their physical health.  Patients 
who were not healthy and whose viral load was high came in every month; 
patients who were in good health only came in every three months; and patients 
who were in excellent health and who had an undetectable viral load came in 
every six months.  The frequency of visits was one of the few characteristics that 
differed between the sites.  Patients who were in better health and who visited 
the clinic less often came mostly from the one clinic located in the suburb.  The 
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only other notable difference was that the clinic located in the suburb had a 
higher socio-economic population. 
 
The clinicians referred all participants to the team and the participants freely 
chose whether they wanted to take part in the study.  Each on-site researcher 
randomly assigned his/her participants into either the control or intervention 
conditions.  After recruitment, the patients completed informed consent 
procedures and baseline measures by participating in their first LifeWindows 
session. 
 
The participants interacted with LifeWindows for approximately 18 months 
between March 2006 and March 2008 in a private location in the HIV clinic prior 
to seeing their provider for routine HIV medical visits. Patients could complete up 
to one LifeWindows session a month and received $20 for each session they 
completed. 
 
Of the 590 patients recruited in the study, 12 had their regimen changed to renal 
dosing during the study period.  Throughout this thesis the group of individuals 
placed on renal dosing is the renal dosing group (or RD), while the entire sample 
population is SP.   
 
Similarities between the Sample Population and Renal Dosing Group: 
Most of the demographics and characteristics of the RD were similar to the SP. 
Throughout both populations in the study there were slightly more male than 
female patients (SP= 61.2% male, RD= 58.3% male).  Most of the population 
identified themselves as heterosexual (SP= 74.1% and RD= 83.3%).  There was 
a slight difference between the groups among those who did not identify 
themselves as heterosexual.  In the total sample 19.2% of the population 
identified themselves as homosexual and 6.7% identified themselves as 
bisexual.  In the renal sample only 8.3% identified themselves as homosexual 
! $+!
and another 8.3% identified themselves as bisexual.  Also, most patients had few 
to no children (SP= 1.17 children, RD= 0.3 children).  
 
Most of patients in the study lived with HIV for more than ten years (SP= 13.25 
years, RD= 14.18 years).  While this is not a significant difference there is a 
chance that the years lived with HIV may be correlated with being on renal 
dosing.  Since long-term use of Tenofovir can cause kidney problems, the longer 
a patient takes the medication the more likely he/she is to develop renal issues.  
Due to the small sample size of RD this thesis cannot test this hypothesis, but 
this may warrant future testing.   
 
The most significant characteristic that the two groups shared was their living 
situation.  The vast majority of the populations lived in stable housing (SP= 
90.9%, RD= 91.6%).  The living situations of the patients did not appear to be a 
factor that affected adherence, yet very few patients had employment (SP= 
39.3%, RD= 25%).  This characteristic greatly affects the socio-economic status 
of the patients and can impact their adherence.  On average, the patients in the 
study lived close to or below the poverty line (SP= $17,219 a year, RD= less than 
$10,000 a year).  I expected this result because those patients on renal dosing 
would work less and make less money than other patients due to the physical 
problems and limitations that kidney failure causes.  It is important to note that 
this survey question asked about family income and there was no way to 
determine if participants included other sources of income (such as welfare or 
supplemental security income) when they answered this question.  This data 
show that income is a characteristic correlated with RD and may be a barrier to 
adherence.  Income may also be a barrier for SP since less than 40% of the 
patients in the study found employment. 
 
Differences between the Renal Dosing group and the Sample Population: 
While the two groups shared many characteristics there a number of 
characteristics differed.  The most notable of these was race/ethnicity.  Most 
! $"!
patients in the study were minorities.  For both samples African American (AA) or 
Black was the largest ethnic group that patients identified.  The sample 
population was 44.1% Black, while the renal dosing group was 66.6% Black.  
Although this is a significant difference, the difference in the sample sizes may 
skew the findings.  It is interesting to note that in the general population kidney 
problems concentrate among those who are Black (Bogart et al. 2010). 
 
While many patients in both samples contracted the virus through heterosexual 
intercourse (SP= 39.1%, RD= 41.6%), the groups differed on the other ways the 
patients contracted the virus.  The largest difference was for those who 
contracted HIV due to intravenous drug use (SP= 21/2%, RD= 41.6%).  While the 
size of the sample may skew the findings, this is also interesting because like 
being AA, IDUs are also more likely to develop kidney issues than non-IDUs in 
the general population (Bogart et al. 2010).  These characteristics and further 
information are below in Table 1.  
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Table 1: Demographic Information and Characteristics 
 
Characteristic 
Total Sample 
Population 
Renal Dosing 
Group 
Male 361 (61.2%) 7 (58.3%) 
Female 229 (38.8%) 5 (41.6%) 
Years with HIV 13.25 14.18 
Number of children 1.17 0.3 
Heterosexual 431 (74.1%) 10 (83.3%) 
Homosexual 112 (19.2%) 1 (8.3%) 
Bisexual 39 (6.7%) 1 (8.3%) 
Living in stable housing 538 (90.9%) 11 (91.6%) 
Black/ African American 262 (44.1%) 8 (66.6%) 
Latino/a 151 (25.4%) 1 (8.3%) 
White 141 (23.7%) 3 (25.0%) 
Other 40 (6.7%) 0 (0.0%) 
Employed 233 (39.3%) 3 (25.0%) 
Yearly income $17,219  Under $10,000 
HIV infection: MSM 85 (14.3%) 2 (16.6%) 
HIV infection: Heterosexual sex 232 (39.1%) 5 (41.6%) 
HIV infection: IDU 126 (21.2%) 5 (41.6%) 
HIV infection: Blood transfusion 15 (2.5%) 0 (0.0%) 
HIV infection: Multiple ways 54 (9.1%) 2 (16.6%) 
HIV infection: Unknown 73 (12.3%) 2 (16.6%) 
HIV infection: Refused to answer 6 (1.0%) 0 
HIV infection: Sex but gender 
unknown 2 (0.3%) 0 (0.0%) 
 
 
Data courtesy of the LifeWindows Project Team 2006 
 
Data: 
 
The LifeWindows project tested the hypothesis that by exposing HIV+ patients to 
interventions that addressed barriers to adherence the patients’ adherence rates 
would increase.  Prior to the study, the literature and conversations with 
providers, all stated that patients must take their ARV medications every day at 
the same time in order for the medications to be effective.  The team designed 
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the computer system and study in this manner to measure adherence by tracking 
whether or not patients took the prescribed dose of each medication every day.  
 
During the study providers changed the ARV regimen of several of their patients.  
Among these were 12 patients that the clinicians placed on renal dosing.  These 
patients suffered from kidney problems that required dialysis.   Since the body 
excretes these HIV medications through the kidneys, the providers changed 
these medications before they became toxic for these 12 patients.  The providers 
changed the dosing for these medications from once every day to once or twice a 
week following a dialysis treatment.   
 
Since the design of the LifeWindows computer program only tracked adherence 
on ARV medications taken every day, the automated program for adherence 
could not assess adherence for these 12 patients.  While adherence was not 
tracked, the automated program captured the barriers to adherence that these 
patients positively identified.  My thesis examines these barriers to adherence to 
see if any of them are unique to this population and to better understand the lives 
of these patients to help increase adherence rates for HIV+ patients placed on 
renal dosing. 
 
Examining the Data: 
The examination of the case notes made by the site researchers identified the 
renal dosing patients in the study.  This examination yielded 12 patients placed 
on renal dosing during the study. These 12 patients hereafter are the renal 
dosing group and the rest of the sample is the normal dosing group. 
 
As previously discussed, each time a patient completed a session of 
LifeWindows he/she answered 45 survey questions that identified 37 possible 
barriers to adherence.  The responses for these 45 questions ranged from two to 
six options (with an additional response of “refuse to answer” for each question).  
For the analysis of this thesis, I coded the responses binomially for uniformity.  If 
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the response did not identify a barrier or if the patient chose “refuse to answer” 
the coded response was a 0.  Since “refuse to answer” did not identify a barrier, 
coding as a 0 omitted this response from the data set.  This coding scheme is 
useful in survey research because refusal to answer is usually unrepresentative 
of a sample and does not change data set (Kent 2001).  If the response identified 
a barrier the coded response was a 1.  These criteria were the same as those 
used in the LifeWindows adherence algorithm that identified which intervention 
strategies the LifeWindows program showed the patients.  
 
The patients’ responses were then sorted chronologically by each LifeWindows 
session they completed.  For this thesis I only used the baseline and final survey 
responses to identify and analyze the barriers to adherence.  These two time 
frames best compare the responses of patients in each of the dosing groups.  
Since all patients entered the study while on normal ARV therapy dosing, the 
renal dosing group did not exist at baseline.  Those patients placed on renal 
dosing remained on a renal dosed regimen throughout the remainder of the 
study.  The final survey clearly divided the normal dosed patients from the renal 
dosed patients.  The final survey responses also reflect longer lasting barriers to 
adherence because the patients had months to acclimate with the change in their 
medication regimen. 
 
Thus, patients had to complete at least two sessions of LifeWindows to be in the 
samples for this thesis.  This thesis does not include data from patients who only 
completed a baseline survey.  The thesis also does not include data from 
patients who failed to answer all of the questions during the baseline or final 
surveys.  This provides an accurate range to detect the barriers identified by 
patients.  The final sample included 12 patients in the renal dosing group and 
513 patients in the normal dosing group.  While the total sample had 590 
participants, due to attrition or lack of answering all questions, only 513 
participants remained in the normal dosing group in this analysis. 
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Data Analysis: 
 
The analysis of the data used the SPSS statistical software package.  The 
analysis used Paired Sample T-Tests, Independent T-Tests, and Chi Squared 
tests to examine whether there were significance differences between the two 
groups and to identify significant barriers to adherence. 
 
Results: 
I analyzed the data to see if there were specific barriers to adherence that only 
the patients on renal dosing identified as a barrier.  I hypothesized that the switch 
to a renal dosed regimen would increase the barriers and difficulties patients had 
in adhering to their ARV medications.  In this analysis I examined the overall 
number of barriers identified by the patients and looked at each survey question 
to determine if it disproportionally affected those patients on renal dosing.  When 
I found barriers that greatly affected the renal group, I then examined these 
barriers further to better understand them and offer recommendations on how to 
help this population increase adherence.  
 
Based on the 45 questions from the LifeWindows survey, each patient identified 
between 0 and 45 questions that positively correlated with a barrier to their ARV 
adherence.  The total number of questions that positively identified barriers to 
adherence for the renal group’s responses compared the group’s baseline and 
exit surveys.  A Paired Sample T-Test found an average of 18.25 questions that 
positively identified barriers on the baseline surveys and an average of 14.58 
questions on the exit surveys.  There was no correlation or significance found in 
these results.  Thus, being placed on renal dosing did not increase the likelihood 
that a patient would experience more barriers to adherence.  This decrease in 
barriers may be a result of exposure to the intervention arm of the study, but this 
is unlikely.  There is no indication that the reduction for renal dosed patients was 
a result of exposure to the intervention arm.  Like the general sample population, 
about half of the patients in the renal group happened to be placed in the 
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intervention arm of the study.  Of the 12 participants, five were in the intervention 
arm and 7 were in the control arm. 
 
For the analysis I used an Independent T-Test to compare the total number of 
questions that positively identified adherence barriers at baseline between the 
two groups.  This analysis showed that at baseline, on average, the total number 
of questions that identified barriers was 18.25 for the renal sample and 15.64 for 
the normal dosing group.  Again the analysis did not find any correlation or 
significance.  I expected this result because at baseline, none of the providers 
placed their patients on renal dosing, thus the two groups had the same number 
of barriers. 
 
The analysis also ran an Independent T-Test on the exit surveys, which 
compared the same total number of questions between the two groups.  This 
analysis showed that at the completion of the study the two groups had, on 
average, almost the same number of questions.  The renal group averaged 14.58 
and the sample group averaged 15.41. Again, the analysis did not find correlation 
or significance.  These results showed that the placement on renal dosing did not 
increase the likelihood that a patient would experience an increase in the total 
number of barriers experienced.  
 
The analysis then analyzed each of the 45 questions to determine if there were 
any particular responses to questions that correlated with the change to a renal 
dosed regimen.  The analysis used the same binomial scale on the 45 questions.  
Any question that more than half of a group (renal or normal) identified as a 
barrier went under further investigation.  This yielded a total of 14 survey 
questions that fit this profile.  These survey barriers are below in Table 2. 
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Table 2: Barriers to Adherence Survey Questions for Further Analysis 
Question Percent 
Who 
Responded 
Barrier Identified 
How hard or easy is it for you to manage the 
side effects of your HIV medications? 
67% Difficulty in managing the side 
effects to medications 
How much bodily pain have you had during 
the past 4 weeks? 
67% Experiencing and dealing with 
bodily pain 
During the past 4 weeks, how much did 
physical health problems limit your usual 
physical activities (such as walking or 
climbing stairs)? 
67% Physical health problems limit 
ability to perform daily functions 
During the past 4 weeks how much difficulty 
did you have doing your daily work, both at 
home and away from home, because of your 
physical health? 
67% Difficulty in performance of daily 
work due to physical health 
problems 
It upsets me that the HIV medications I have 
been prescribed can cause side effects 
66% Fear of a medication's side 
effects 
During the past 4 weeks, how much energy 
did you have? 
63% Lack of energy 
I am worried that other people might realize 
that I am HIV+ if they see me taking my 
medications 
58% Fear that others may find out 
about HIV status if medications 
are taken in public 
How hard or easy is it for you to take your 
HIV medications when you do NOT feel 
good physically 
58% Difficulty in taking medications 
when not feeling good physically 
It upsets me that the HIV medications I have 
been prescribed can affect the way I look 
57% Negative feelings towards 
medications 
How often do you use a pillbox to help keep 
track of your HIV medications? 
57% Not using a pillbox or other 
reminder device 
It frustrates me to think that I will have to 
take these HIV medications every day for 
the rest of my life 
57% Frustration that HIV medications 
must be taken for life 
I get frustrated taking my HIV medication 
because I have to plan my life around them 
54% Frustration in having to plan life 
around medications 
How hard or easy is it for you to take your 
HIV medications when you do not feel good 
emotionally (for example, when you are 
depressed, sad, angry, or stressed out)? 
53% Not feeling good emotionally 
How hard or easy is it for you to take your 
HIV medications when your usual routine 
changes (for example, when you travel or 
when you go out with your friends)? 
50% Changes in one's daily routine 
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For each of the questions above the analysis compared the baseline and final 
surveys for each participant.  The analysis then summed the total number of 
patients that identified the question topic as a barrier for both the renal and 
normal dosing groups.  Chi square tests using Yates correlation (since the size of 
the groups differed) compared the total number of barrier questions at baseline 
and exit time periods for both the renal dosing and normal dosing groups.  
 
The expected outcome was that the analysis would identify certain barriers within 
the renal dosing group only, due to the additional challenges the patients in the 
renal dosing group faced.  The data yielded from the analysis do not support this 
hypothesis.  Of the 45 questions examined, only one (I am worried that other 
people might realize that I am HIV+ if they see me taking my HIV medications) 
was statistically significant.  Surprisingly, this barrier was a problem for the 
normal dosing group and not the renal dosing group.  Thus, the analysis found 
no barriers that significantly affected renal dosing patients more than normal 
dosing patients. 
  
The lack of statistical significance in the data analysis most likely reflects the 
small sample size of the renal dosing group.  While I found no statistical 
significance from the quantitative analysis, I decided to conduct a qualitative 
analysis by using an inductive grounded theory approach (Bernard 2004).  I 
examined the 14 questions that patients identified as a possible barrier to 
adherence in order to identify possible trends in noncompliance.  I reviewed each 
of the questions and identified themes that the questions had in common.  An in-
depth review of this analysis follows. 
 
Discussion: Factors to Noncompliance and the Barriers to Adherence: 
 
Through the use of the grounded theory analysis I found that there were some 
questions that the renal group identified as barriers, some that the normal group 
identified as barriers, and some questions that both groups identified as barriers.  
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The examination of these questions and their strategies led to several possible 
factors that may cause these barriers.  These factors are below in Table 3. 
 
Table 3: Factors to Noncompliance 
 
Group Affected Factor 
1)   Emotional well-being and psychological mindset Barriers that greatly affected 
patients in both groups 2)   Physical Factors that lie outside of a person’s control    
1)   Side Effects to medications Barriers that affected 
patients on renal dosing 
more 
2)   Physical Health problems 
Barriers that affected 
patients on normal dosing 
more 
1)   Interruptions in daily life  
Barrier that affected both 
groups but was not part of 
the survey.  Field site 
personnel identified this 
barrier. 
1)   Health Literacy 
 
 
Barriers for All Patients: 
While not expected, the data revealed a series of barriers that affected patients in 
both of the groups.  The quantitative analysis did not find this because the 
analysis focused on finding the differences between the two groups.  The barriers 
that both groups identified are in Table 4. 
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Table 4: Barriers Identified by Both Groups 
 
Question Percent 
who 
Responded 
Factor Barrier Identified 
It upsets me that the HIV 
medications I have been 
prescribed can cause side 
effects 
66% Emotional 
well-being 
and 
psychological 
mindset  
Fear of a 
medication's side 
effects 
How hard or easy is it for you 
to take your HIV medications 
when you do not feel good 
emotionally (for example, 
when you are depressed, sad, 
angry, or stressed out)? 
53% Emotional 
well-being 
and 
psychological 
mindset  
Not feeling good 
emotionally 
During the past 4 weeks, how 
much energy did you have? 
63% Physical 
factors that 
lie outside of 
a person's 
control 
Lack of energy 
How hard or easy is it for you 
to take your HIV medications 
when your usual routine 
changes (for example, when 
you travel or when you go out 
with your friends)? 
50% Physical 
factors that 
lie outside of 
a person's 
control 
Changes in one's 
daily routine 
 
 
The first two barriers identified by both groups related to the emotional wellbeing 
and psychological mindset of the patient.  HIV+ patients suffer from a number of 
psychological and emotional issues.  There are many aspects of living with HIV 
that cause distress for patients and if a patient is not feeling emotionally well, this 
can impact adherence (Tuck & McCain 2008).  The fear of possible side effects 
from HIV medications can be very distressing to patients.  As previously 
discussed, many medications can cause side effects, but HIV medications have 
some of the harshest side effects on patients.  Thus, it makes sense to find these 
two barriers shared by both patient groups. 
 
The second set of barriers identified by both groups focused on patients’ 
experiences in dealing with physical factors that usually lie outside of their 
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control.  A further review of the literature found that this trend is expected.  It is 
well documented that many HIV+ people experience a lack of energy due to the 
virus, side effects from medications, or other health conditions (Adinolfi 2001).   
 
The other physical barrier to adherence that both groups identified was difficulty 
in adhering to a medication regimen due to a change in daily routine.  This 
particular barrier is also common among the HIV community although it is not 
exclusive to those on HAART.  In fact most people, not just HIV positive people, 
forget or unable to take their medications when their routine changes (Rosner 
2006 and Waller & Altshuler 1986).  While these are well-known barriers, the 
data show that these barriers still exist for both populations and that further 
investigation into these barriers is necessary to understand the full impact that 
they have on adherence.   
 
Barriers for Patients Placed on Renal Dosing: 
While not statistically significant, the data revealed a number of barriers that 
affected patients in the renal dosing group more than those in the normal dosing 
group.  These barriers are below in Table 5. 
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Table 5: Barriers for Patients Placed on Renal Dosing Schedules 
 
Question Percent 
who 
Responded 
Factor Barrier Identified 
How hard or easy is it for you 
to manage the side effects of 
your HIV medications? 
67% Side Effects 
to 
medications 
Difficulty in 
managing the side 
effects to 
medications 
How much bodily pain have 
you had during the past 4 
weeks? 
67% Physical 
health 
problems 
Experiencing and 
dealing with bodily 
pain 
During the past 4 weeks, how 
much did physical health 
problems limit your usual 
physical activities (such as 
walking or climbing stairs)? 
67% Physical 
health 
problems 
Physical health 
problems limit ability 
to perform daily 
functions 
During the past 4 weeks how 
much difficulty did you have 
doing your daily work, both at 
home and away from home, 
because of your physical 
health? 
67% Physical 
health 
problems 
Difficulty in 
performance of daily 
work due to physical 
health problems 
How hard or easy is it for you 
to take your HIV medications 
when you do NOT feel good 
physically 
58% Physical 
health 
problems 
Difficulty in taking 
medications when 
not feeling good 
physically 
 
The first barrier identified by the renal group dealt with difficulties in the 
management of side effects.  Both groups identified that knowing that HAART 
could cause side effects was barrier, but this finding may show an important 
difference between the two groups.  It is unclear as to whether the normal group 
did not experience side effects or just did not have issues managing their side 
effects.  It is clear that the renal group had issues in dealing with the side effects 
of their medications. 
 
There may be several reasons why side effects are more burdensome for renal 
dosed patients.  As previously discussed, studies revealed that medications like 
Tenofovir had the side effect of renal failure, which forced patients to receive 
dialysis treatments.  The reception of dialysis treatments could very well explain 
this difference between the two groups. 
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The comorbidity of HIV and kidney problems may also explain this difference.  
Poor renal function increases the likelihood of adverse drug reactions and side 
effects (Jick 1977).  The combination of these two factors results in a syndemic 
that may explain why this barrier is not shared with normally dosed HIV+ 
patients.   
 
The remaining barriers all dealt with the physical health of the patient.  While HIV 
may take its toll on the body and be quite painful, the additional issues in 
experiencing renal failure and undergoing constant dialysis treatments can be 
much worse.  Kidney failure is extremely uncomfortable and causes intense pain 
in the kidney area (Pham et al. 2010).   In addition to experiencing pain, dialysis 
treatments can leave a patient weak and unable to perform many of his/her 
everyday activities (Polaschek 2003).  These barriers can affect whether a 
patient is actually able to take his/her medications and the medications can also 
affect the emotional mindset of the patient and how he/she feels about the 
medications and about HIV. 
 
Barriers for Patients Placed on Normal Dosing: 
Since the hypothesis was that renal dosed patients would have a harder time 
adhering to their medications, the data analysis attempted to find barriers unique 
to those patients who were on renal dosing.  Although not expected, the data 
identified barriers that affected the normal dosed patients more than the renal 
dosed patients.  These barriers are below in Table 6. 
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Table 6: Barriers for Patients Placed on Normal Dosing Schedules 
 
Question Percent 
who 
Responded 
Factor Barrier Identified 
I am worried that other people 
might realize that I am HIV+ if 
they see me taking my 
medications 
58% Privacy Fear that others 
may find out about 
HIV status if 
medications are 
taken in public 
It upsets me that the HIV 
medications I have been 
prescribed can affect the way I 
look 
57% Privacy Negative feelings 
towards medications 
How often do you use a pillbox 
to help keep track of your HIV 
medications? 
57% Privacy/ 
Interruptions 
in daily life 
Not using a pillbox 
or other reminder 
device 
It frustrates me to think that I 
will have to take these HIV 
medications every day for the 
rest of my life 
57% Interruptions 
in daily life 
Frustration that HIV 
medications must be 
taken for life 
I get frustrated taking my HIV 
medication because I have to 
plan my life around them 
54% Interruptions 
in daily life 
Frustration in having 
to plan life around 
medications 
 
 
The first three of the barriers identified by the normal dosing group, revolved 
around issues dealing with privacy. The first of these barriers centered on the 
problem of taking one’s medications in private.  This was in fact the only barrier 
that was significant when compared between the two groups.  Due to the small 
sample size, this finding cannot be representative of the greater HIV population.  
It is interesting though that for this group of patients, the fear of taking HAART in 
public is not a barrier for the renal dosed patients. A possible explanation may be 
that because these patients are so ill that their kidney problems make it too 
difficult to hide their health problems.  If future studies show similar findings, then 
future researchers may want to examine this hypothesis.   
 
Another explanation is the fact that the renal dosed group takes their medications 
less frequently making the taking of medications in private easier.  It is also likely 
that the patients pair this barrier with the fear of disclosing one’s HIV status.  If 
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patients’ immune systems are healthy, it can be easier to hide their status.  
Trying to hide an illness such as renal failure can be very difficult because of the 
pain that renal failure causes or the time necessary to receive dialysis 
treatments, which can leave patients weakened and unable to function normally 
(Johansen et al. 2003).  It is possible that these factors may lead the renal 
patients to rely on others for help and in turn, disclose their HIV status.    
 
The second barrier identified by this group also centered around the factor of 
privacy but dealt with the fear that the side effects of a medication could affect 
one’s physical appearance.  If an HIV medication causes physical side effects 
such as lipodystrophy (subcutaneous fat deposits found in the body) or 
lipoatrophy (the loss of subcutaneous fat), it is very hard for a patient to hide a 
side effect such as this or try to explain its causes.  Similar to the second barrier, 
the third barrier focused on the use of a pillbox in remembering to take one’s 
medications.  Like a physical side effect, if a person uses a pillbox it may become 
difficult to keep this hidden and take the medications in private.  Another 
explanation for this third barrier is that it may be difficult to use a pillbox due to 
the complexities of daily life.   
 
The lack of the presence of renal impairment for these HIV+ individuals could 
explain this trend.  HIV is unfortunately a highly stigmatized disease while renal 
impairment on the other hand is not (Rintamaki et al. 2006).  The renal dosed 
individuals can disclose their renal impairment and used it as an explanation for 
their health problems.  They could use this to explain why they take medications 
during the day and why they suffer from side effects to medications.  Blaming 
some of these health problems on the renal impairment can allow these 
individuals to receive an understanding from others while still not disclosing their 
HIV status.  The patients in the normal dosed group may not have another health 
condition to fall back on to blame their health problems to the public. 
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The final two barriers dealt with interruptions in daily life and showed that HIV+ 
patients can become frustrated with the ways that their medications affect them 
and their daily lives.  As the effectiveness of HAART increased over time, HIV 
became a chronic disease and not just a death sentence.  At the same time, 
there is no cure for HIV and reliance on HAART for the rest of patients’ lives can 
be very frustrating.  One reason why the renal dosed group did not identify these 
barriers might be because those on renal dosing face a more invasive treatment 
with dialysis.  These patients may also view their kidney disease as a terminal 
illness.  Many dialysis patients suffer from depression and are more likely to think 
about and commit suicide (Kurella 2005). 
 
Because only the normal dosing group identified these barriers, these barriers 
should go under further investigation to understand their true nature.  It may also 
be beneficial to understand why these are not barriers for the renal dosed 
patients in order to help future patients who are not on renal dosing.  
 
Health Literacy: 
While conducting the study, several of the site researchers reported that by 
taking part in the experiment, many of the patients became confident about their 
HIV medications.  The site researchers reported that in the early stages of the 
study many of the patients did not know the names of their prescribed 
medications and could rarely describe what they looked like.  The experimenters 
also noted that many of these patients did not know the difference between their 
HIV medications and medications used to treat other health conditions. 
 
This trend occurred in both the renal and normal dosing groups, and at all five of 
the research sites.  Added confusion existed for many of the renal dosed patients 
because the computer program did not measure adherence for their renal dosed 
medications.  The site researchers had to leave these particular medications out 
of the system’s memory when consulting the medical records.  One on-site 
researcher reported that one patient insisted that he continued to take the renal 
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dosed medication every day.  Yet the medical record and clinician’s report 
showed that this was not the case.  
 
As the study progressed fewer instances of medication discrepancies, amongst 
all patients, occurred.  While this result was not surprising, because the patients 
grew familiar with the program over time, the field staff noted additional changes.  
Over time the patients felt confident about which medications the clinicians 
prescribed them.  The site staff also stated that the patients appeared to display 
pride in knowing information about their medications.  This was conveyed by the 
patients verbally telling the researchers how they felt or by the patients’ facial and 
body expressions when they completed the pill-picker section.  
 
The concept of health literacy can best explain this finding.  Health literacy is “the 
degree to which individuals have the capacity to obtain, process, and understand 
basic health information and services needed to make appropriate health 
decisions” (U.S. Department of Health and Human Services 2000).  Health 
literacy is important for ARV therapy adherence because the more health literate 
HIV+ patients become the more likely they are to adhere to their HIV medication 
regimen (Kalichman, Ramachandran, & Catz 1999). 
 
Simply by learning the names of their medications the patients became more 
informed about their health and their medications.  Yet, knowing the name of a 
medication is far from being considered health literate; and health literacy among 
the HIV population is very limited.  This is because, for the most part, the HIV 
population comprises individuals that are unfortunately marginalized by society.  
This includes populations such as minorities, gay men, prisoners, and IDUs.  
Many HIV+ people in America are from low socio-economic levels in society and 
lack the education and resources needed to learn about their disease.     
 
The research team’s interactions with HIV+ patients supported many of these 
stereotypes.  The clinical sites locations were urban centers throughout the state 
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and nearly all of the patients suffered from a low socio-economic status.  These 
patients demonstrated a low level of health literacy and appeared to know very 
little about their medications at the beginning of the study. 
 
When a provider places a patient on renal dosing, the lack of health literacy 
becomes even worse.  Most HIV medication regimens contain multiple 
medications.  Yet, very few medications cause nephrotoxicity.  So when a 
provider places a patient on a renal dosed regimen the nephrotoxic medication is 
usually the only one not taken every day.  The provider, who once convinced the 
patient that he/she needed to take all his/her HIV medications every day, must 
now try to explain the changes to the patient’s regimen.  In a patient with low 
health literacy it can be very difficult for the provider to explain the changes in the 
medication regimen.  It is even harder for the provider to try to explain why the 
change occurred and how, although the medication damaged the kidneys, 
adherence to the medication is necessary for viral suppression.   
 
If a provider cannot convey this information in a way that the patient understands, 
adherence is at jeopardy because this is one of the main factors to adherence in 
the IMB model.  It is also difficult for a provider to assess how much of the 
information the patient understands.  Due to the power relations of the patient-
provider relationship and cultural differences “the absence of discourses about 
rationing and the limits of therapeutic medicine reproduce old racialized tropes 
and lead us into explanatory circles when it comes to trying to understand racial 
health disparities” (Rousse 2010).  If trust is not the foundation of the patient-
provider relationship, meaningful and forthright conversations about adherence 
and barriers to adherence are unlikely to occur (Bangsberg et al. 2001 and 
Roberts 2000). 
 
Renal dosing is relatively new to the HIV world.  Further research on the health 
literacy of renal dosed patients can yield important information to providers and 
researchers.  By increasing patients’ health literacy providers can convey more-
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accurate information to patients.  With this information, patients can better 
understand their HIV, medications, and the therapeutic strategies on.  This will be 
of extreme importance with the expected rise in numbers of renal dosed HIV 
patients. 
 
Conclusion: 
 
Adherence to an ARV medication regimen is fundamental for viral suppression.  
Identifying and addressing patients’ barriers to adherence can increase rates of 
adherence.  Renal dosing of HIV medications is still relatively new, and the 
literature on adherence to HAART for this group is severely lacking.  Further 
investigation into understanding the management of side effects and how HIV 
and renal failure act on the physical health of patients is the first step to truly 
addressing the barriers these patients may face. 
 
This thesis examined the barriers to adherence that HIV+ patients in the 
LifeWindows study identified.  During the study some of the patients had their 
medications changed to a renal dosing regimen.  The LifeWindows adherence 
survey positively identified several barriers to adherence.  Statistical data 
analysis did not find a significant difference between the two groups as a whole 
or in relation to a particular question on the survey.  Further exploration, from a 
qualitative perspective with the use of grounded theory, found possible trends 
among the groups.  This thesis discussed possible explanations for the presence 
of these barriers in order to better understand these barriers.  The presence of 
such barriers shows that more work is necessary in order to provide information 
and resources to these HIV+ patients. 
 
Limitations: 
The biggest limitation of this thesis was the small sample size of the renal dosing 
population.  Due to the small sample size the power was insufficient.  This may 
be why the data analysis did not find significance in the results.  Unfortunately 
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this was unavoidable since the number of patients in the clinics placed on renal 
dosing was very small.  In fact the providers placed about 2% of the sample on 
renal dosing.  This sample may be a fair representation of the HIV population in 
America because only 2% of the population is on renal dosing (Hamzah & Post 
2009).  Yet, it is important to note that participation in the intervention arm did not 
affect the barriers identified or the rates of adherence for this group. 
 
Another limitation of this study was that the computer program could not capture 
data on adherence for the renal dosed medications themselves.  In order to 
garner a clearer picture of these barriers, data on adherence may be necessary.  
Another limitation was the dichotomizing of patient responses.  To compare the 
patients’ responses across questions the analysis required a standardized set of 
responses.  Since the survey questions possessed a wide range of responses, 
the analysis required the responses to be binomial to be uniform.  While this 
allowed comparison between questions it also limited understanding of the 
degree to which these barriers affected the patients. 
 
The final limitation in this thesis was that the survey was a structured interview in 
which patients had a limited number of responses to choose from.  This limitation 
did not affect the overall LifeWindows study, but it did affect the data captured on 
those patients whose providers switched them to a renal dosing regimen.  Since 
there is very little known about renal dosing, obtaining an emic perspective would 
allow the renal dosed patients to explain more about their experiences with their 
medications.  
 
Future Recommendations: 
The analysis found 14 barriers to adherence that more than half of the population 
of either the renal dosed group or normal dosed group identified.  Future 
research should test these barriers against a larger population of renal dosed 
patients.  A larger population can accurately gauge whether or not these barriers 
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are significant.  Also, a larger population may provide results that researchers 
could generalize to the larger HIV population. 
 
While a larger population size of renal dosed patients is necessary, both groups 
identified four barriers.  These barriers are of major concern because they 
impacted both groups.  Therefore researchers should study these barriers right 
away.  The barriers that only the normal dosed patients identified should also go 
under further investigation in relation to the renal dosed patients.  It may prove 
useful to understand why certain barriers are not problematic for those patients 
on renal dosing. 
 
It would be very instructive to conduct semi-structured interviews in future 
studies.  These interviews could examine the questions on the survey in more 
depth and allow future researchers to obtain a more in-depth, emic perspective 
from the patients.  The following examples provide reasons why an in-depth emic 
perspective is necessary to understand the illness narratives of the patients: 
 
1) All patients identified the fear of side effects as a possible barrier to 
adherence.  The normal group did not have a problem managing the side 
effects of their medications while the renal group did.  This does not tell us 
if the normal dosed patients could manage their side effects effectively or 
if they did not experience side effects at all. 
 
2) The renal group identified physical health problems as a barrier to 
adherence.  While this barrier may exist for this population, the data do not 
tell us if this is related to the problems these patients have with their 
kidney failure or not. 
 
3) Both groups identified difficulty in taking their medications when they did 
not feel emotionally well.  According to the survey, not feeling emotionally 
well included: depression, sadness, anger, and stress.  While these are all 
! &#!
negative emotions, there are differences between them.  It may be 
necessary to determine which emotion patients experience and what 
caused the patients to feel that way.  Treatment and coping for each of 
these emotions may be different.  An argument could also be made that 
since most patients in the study did not feel emotionally well, all patients 
may need better mental health therapy. 
 
As previously stated, the research conducted on adherence for HIV+ patients 
placed on renal dosing ARV medication regimens is scarce.  This thesis is the 
starting point of adherence research for this population and can help guide future 
research.  Researchers should use these results to further investigate this 
population to determine if these trends are unique to this study or are 
representative of the greater population.  Since the rates of renal dosing of HIV 
medications will most likely increase in the coming years, it is important to 
understand the barriers to adherence for this population while its size remains 
small.  By doing so, we can develop interventions and strategies to combat 
noncompliance before the population size increases.  Thus, more research on 
this topic is necessary.  
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Appendix 
 
Table 7: LifeWindows Demographic Survey Questions 
Item Question Response 
1 ! African American or Black 
! American Indian or 
Alaskan Native 
  ! Hispanic American or Latino(a) 
! Native Hawaiian or Other 
Pacific Islander 
  ! White (not Hispanic) ! Other 
  
What is your 
racial/ethnic 
background? 
(Please click all that 
apply.) 
! Asian American   
2 
Are you…? (Please 
click one.) ! Male 
! Transgender 
    ! Female ! Intersexed 
3 ! Some high school or less ! College degree (BA, BS) 
  ! High school diploma or GED ! Some graduate school 
  
What is the highest 
level of education 
you have 
completed? (Please 
click one.) ! Some college 
! Graduate degree (MA, JD, 
PhD, MD, etc) 
4 ! Under $5,000 ! $30,001 to $50,000 
  ! $5,000 to $10,000 ! $50,001 to $75,000 
  ! $10,001 to $20,000 ! Over $75,000 
  
What is your family 
income per year? 
(Please click one. If 
you don't know, 
please make your 
best guess.) ! $20,001 to $30,000   
5 ! 1 (myself)                         ! 6 
  ! 2 ! 7 
  ! 3 ! 8 
  ! 4 ! 9 
  
How many people 
are supported by this 
income, including 
yourself? (Please 
click one.) 
! 5 ! 10 or more 
6 ! Living on the street.   
  ! Living in an abandoned building.   
  ! Living in a homeless shelter.   
  ! Living in a halfway house, assisted living residence, or rehabilitation program. 
  ! Living in a friend's or family member's house or apartment. 
  
Where are you living 
right now? (Please 
click one.) 
! Living in a house, condominium, apartment or room that you rent or own. 
7 ! Gay or lesbian ! Bisexual 
  
What is your sexual 
orientation? (Please 
click one.) ! Straight or heterosexual ! Unsure / don’t know 
8 ! Having sex with a man who had HIV ! Blood transfusion 
  ! Having sex with a woman who had HIV ! Got it at birth 
  
How do you think 
you got HIV? 
(Please click all that 
apply. If you are 
unsure, please make 
your best guess.) ! Sharing needles or works ! Don't know 
9 
In what year were 
you diagnosed with 
HIV? (Please click 
one.) 
1980-2006 
  
10 ! 0 (no children) ! 4 
  ! 1 ! 5 
  ! 2 ! 6 or more children 
  
How many children 
do you care for in 
your home? (Please 
click one.) 
! 3   
11 ! Currently unemployed ! On disability or sick leave 
  ! Employed part-time ! Retired 
  
What statement best 
describes your 
employment status? 
(Please click one.) 
! Employed full-time   
! '%!
 
Table 8: LifeWindows Barriers to Adherence Survey Questions 
 
Question Response Barrier Identified 
o Yes 
o No  Not adhering to ARV therapy 
Are you now taking a break from your HIV 
medications without having talked to your 
healthcare provider about it?  (Please click one.) 
   
o I strongly disagree 
o I somewhat disagree 
Lack of knowledge about HIV and ARV 
therapy 
o I neither agree nor 
disagree 
  
o I somewhat agree   
o I strongly agree   
As long as I am feeling healthy, missing my HIV 
medications from time to time is OK. 
   
o Not at all 
Not feeling good emotionally 
o Very little   
o Somewhat   
o Quite a lot   
During the past 4 weeks, how much did personal or 
emotional problems keep you from doing your 
usual work, school or other daily activities? 
o Could not do daily 
activities 
  
o Not at all 
o Very little 
Physical health problems limit ability to 
perform daily functions 
o Somewhat   
o Quite a lot   
During the past 4 weeks, how much did physical 
health problems limit your usual physical activities 
(such as walking or climbing stairs)? 
o Could not do physical 
activities 
  
o Not at all 
o Quite a lot 
Difficulty in engaging in social activities 
due to health problems 
o Very little   
o Somewhat   
During the past 4 weeks, how much did your 
physical health or emotional problems limit your 
usual social activities with family or friends? 
o Could not do social 
activities 
  
o None at all 
o A little bit 
Difficulty in performance of daily work 
due to physical health problems 
o Some   
o Quite a lot   
During the past 4 weeks, how much difficulty did 
you have doing your daily work, both at home and 
away from home, because of your physical health?  
o Could not do daily 
work 
  
o Very much 
Lack of energy 
o Quite a lot   
o Some   
o A little bit   
During the past 4 weeks, how much energy did you 
have? 
o None   
! '&!
o Not at all 
Not feeling good emotionally 
o Slightly   
o Moderately   
o Quite a lot   
During the past 4 weeks, how much have you been 
bothered by emotional problems (such as feeling 
anxious, depressed, or irritable)? 
o Extremely   
o Very hard 
Financial Issues 
o Hard   
o Neither hard nor easy   
o Easy   
o Very easy   
How hard is it for you to pay for your HIV 
medications each month? (Please click one.) 
o I don't pay anything   
o Very Hard 
Lack of social support structures 
o Hard   
o Sometimes hard, 
sometimes easy 
  
o Easy   
o Very Easy   
   
How hard or easy is it for you to get the support you 
need from others for taking your HIV medications 
(for example, from friends, family, doctor, or 
pharmacist)? 
   
o Very Hard 
Difficulty in refilling prescriptions 
o Hard   
o Sometimes hard, 
sometimes easy 
  
o Easy   
How hard or easy is it for you to get your HIV 
medication refills on time? 
o Very Easy   
o Very Hard 
o Hard 
Difficulty in making medications a part 
of daily life 
o Sometimes hard, 
sometimes easy 
  
o Easy   
o Very Easy   
How hard or easy is it for you to make your HIV 
medications part of your daily life? 
   
o Very Hard 
o Hard 
Difficulty in managing the side effects to 
medications 
o Sometimes hard, 
sometimes easy 
  
o Easy   
o Very Easy   
How hard or easy is it for you to manage the side 
effects of your HIV medications? 
   
! ''!
o Very Hard 
Forgetting to take medications 
o Hard   
o Sometimes hard, 
sometimes easy 
  
o Easy   
o Very Easy   
How hard or easy is it for you to remember to take 
your HIV medications? 
   
o Very Hard 
Difficulty in gathering information 
o Hard   
o Sometimes hard, 
sometimes easy 
  
o Easy   
How hard or easy is it for you to stay informed 
about HIV treatment? 
o Very Easy   
o Very Hard 
Problem taking pills 
o Hard   
o Sometimes hard, 
sometimes easy 
  
o Easy   
o Very Easy   
How hard or easy is it for you to take your HIV 
medications because the pills are hard to swallow, 
taste bad, or make you sick to your stomach? 
   
o Very Hard 
Forgetting to take medications 
o Hard   
o Sometimes hard, 
sometimes easy 
  
o Easy   
o Very Easy   
How hard or easy is it for you to take your HIV 
medications when you are wrapped up in what you 
are doing? 
   
o Very Hard 
Not feeling good emotionally 
o Hard   
o Sometimes hard, 
sometimes easy 
  
o Easy    
o Very Easy   
How hard or easy is it for you to take your HIV 
medications when you do not feel good emotionally 
(for example, when you are depressed, sad, angry, 
or stressed out)? 
   
o Very Hard 
o Hard 
Difficulty in taking medications when not 
feeling good physically  
o Sometimes hard, 
sometimes easy 
  
o Easy   
o Very Easy   
How hard or easy is it for you to take your HIV 
medications when you do NOT feel good 
physically? 
   
! '(!
o Very Hard 
o Hard 
Lack of knowledge about HIV and ARV 
therapy 
o Sometimes hard, 
sometimes easy 
  
o Easy    
o Very Easy   
How hard or easy is it for you to take your HIV 
medications when you feel good physically and 
don’t have any symptoms of your HIV disease? 
   
o Very Hard 
Changes in one’s daily routine 
o Hard   
o Sometimes hard, 
sometimes easy 
  
o Easy   
o Very Easy   
How hard or easy is it for you to take your HIV 
medications when your usual routine changes (for 
example, when you travel or when you go out with 
your friends)? 
   
o Very Hard 
o Hard 
Poor patient-provider communication 
o Sometimes hard, 
sometimes easy 
  
o Easy   
o Very Easy   
How hard or easy is it for you to talk to your 
healthcare provider about your HIV medications? 
   
o None 
o Very mild 
Experiencing and dealing bodily pain 
o Mild   
o Moderate   
o Severe   
How much bodily pain have you had during the 
past 4 weeks? 
o Very severe   
o Never 
o Once in a while 
Not using a pillbox or other reminder 
device 
o Half the time   
o Usually   
How often do you use a pillbox to help keep track of 
your HIV medications? (Please click one.) 
o Always   
o I strongly disagree 
o I somewhat disagree 
o I neither agree nor 
disagree 
Fear that others may find out about HIV 
status if medications are taken in public  
o I somewhat agree   
I am worried that other people might realize that I 
am HIV+ if they see me taking my HIV medications. 
o I strongly agree   
! ')!
o I strongly disagree 
Fear of a medications’ side effects 
o I somewhat disagree   
o I neither agree nor 
disagree 
  
o I somewhat agree   
I am worried that the HIV medications I have been 
prescribed will hurt my health. 
o I strongly agree   
o I strongly disagree 
o I somewhat disagree 
Lack of knowledge about HIV and ARV 
therapy 
o I neither agree nor 
disagree 
  
o I somewhat agree   
I believe that if I take my HIV medications as 
prescribed, I will live longer. 
o I strongly agree   
o I strongly disagree 
o I somewhat disagree 
Negative emotions towards HIV and/or 
ARV therapy 
o I neither agree nor 
disagree 
  
o I somewhat agree   
I don’t like taking my HIV medications because they 
remind me that I am HIV+. 
o I strongly agree   
o I strongly disagree 
o I somewhat disagree Poor patient-provider communication 
o I neither agree nor 
disagree 
  
o I somewhat agree   
I feel that my healthcare provider takes my needs 
into account when making recommendations about 
which HIV medications to take. 
o I strongly agree   
o I strongly disagree 
o I somewhat disagree 
Frustration in having to plan life around 
medications 
o I neither agree nor 
disagree 
  
o I somewhat agree   
I get frustrated taking my HIV medications because 
I have to plan my life around them. 
o I strongly agree   
o I strongly disagree 
o I somewhat disagree 
Lack of knowledge about HIV and ARV 
therapy 
o I neither agree nor 
disagree 
  
o I somewhat agree   
I know how each of my current HIV medications is 
supposed to be taken (for example whether or not 
my current medications can be taken with food, 
herbal supplements, or other prescription 
medications). 
o I strongly agree   
o I strongly disagree 
o I somewhat disagree 
Substance abuse: drugs and/or alcohol 
o I neither agree nor 
disagree 
  
o I somewhat agree   
I know how my HIV medications interact with 
alcohol and street drugs. 
o I strongly agree   
o I strongly disagree 
o I somewhat disagree 
Lack of knowledge about ARV therapy 
in relation to side effects 
o I neither agree nor 
disagree 
  
o I somewhat agree   
I know what the possible side effects of each of my 
HIV medications are. 
o I strongly agree   
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o I strongly disagree 
o I somewhat disagree 
Lack of knowledge about ARV therapy 
in relation of missing a dose 
o I neither agree nor 
disagree 
  
o I somewhat agree   
I know what to do if I miss a dose of any of my HIV 
medications (for example, whether or not to take 
the pill(s) later). 
o I strongly agree   
o I strongly disagree 
o I somewhat disagree 
Lack of knowledge about HIV and ARV 
therapy 
o I neither agree nor 
disagree 
  
o I somewhat agree   
I understand how each of my HIV medications 
works in my body to fight HIV. 
o I strongly agree   
o I strongly disagree 
o I somewhat disagree 
Lack of knowledge about HIV and ARV 
therapy 
o I neither agree nor 
disagree 
  
o I somewhat agree   
If I don’t take my HIV medications as prescribed, 
these kinds of medications may not work for me in 
the future. 
o I strongly agree   
o I strongly disagree 
o I somewhat disagree 
Frustration that HIV medications must 
be taken every day for life 
o I neither agree nor 
disagree 
  
o I somewhat agree   
It frustrates me to think that I will have to take these 
HIV medications every day for the rest of my life. 
o I strongly agree   
o I strongly disagree 
o I somewhat disagree 
Negative feelings towards medications 
because side effects can affect the 
physical appearance 
o I neither agree nor 
disagree 
  
o I somewhat agree   
It upsets me that the HIV medications I have been 
prescribed can affect the way I look. 
o I strongly agree   
o I strongly disagree 
Fear of a medication’s side effects 
o I somewhat disagree   
o I neither agree nor 
disagree 
  
o I somewhat agree   
It upsets me that the HIV medications I have been 
prescribed can cause side effects. 
o I strongly agree   
o I strongly disagree 
Lack of social support structures 
o I somewhat disagree   
o I neither agree nor 
disagree 
  
o I somewhat agree   
o I strongly agree   
Most people who are important to me who know I’m 
HIV positive support me in taking my HIV 
medications. 
o No one that I care 
about knows I am 
positive 
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o I strongly disagree 
Lack of social support structures 
o I somewhat disagree   
o I neither agree nor 
disagree 
  
o I somewhat agree   
My healthcare provider doesn’t give me enough 
support when it comes to taking my medications as 
prescribed. 
o I strongly agree   
o Excellent 
Being in a state of poor health  
o Very good   
o Good   
o Fair   
o Poor   
Overall, how would you rate your health during the 
past 4 weeks? 
o Very poor   
o I strongly disagree 
o I somewhat disagree 
Lack of knowledge about HIV and ARV 
therapy  
o I neither agree nor 
disagree 
  
o I somewhat agree   
Skipping a few of my HIV medications from time to 
time would not really hurt my health. 
o I strongly agree   
o I strongly disagree 
o I somewhat disagree 
o I neither agree nor 
disagree 
Substance abuse: drugs/and or alcohol  
o I somewhat agree   
o I strongly agree   
There are times when it is hard for me to take my 
HIV medications when I drink alcohol or use street 
drugs. 
o Not Applicable (I don’t 
drink alcohol or use 
street drugs) 
  
o Never 
o Over a month ago 
Substance abuse: drugs and/or alcohol When was the last time you injected or “shot up” 
street drugs (such as heroin or cocaine)? 
o In the past month   
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Table 9: LifeWindows Intervention Modules 
 
 
Intervention Module  Description 
Battle for Health  
A video game in which patients battle 
infections, take ARV on-time to fight HIV, and 
use tools (e.g., pillboxes, alarms) to ensure 
that ARV are taken, even in challenging 
situations. 
Bill the Pill  
An animated character presents strategies for 
taking pills that are hard to swallow or taste 
bad, taking large numbers of pills, and taking 
medications that make one feel nauseous. 
Celebrate Success 
Offered to patients with perfect adherence. 
Patients create a personalized reward 
certificate and then learn about maintaining 
adherence over time. 
Doc Talk 
A video-based intervention in which patients 
can “ask” HIV doctors about a number of HIV-
related issues, including HIV treatment, side 
effects, and resistance. 
Felicia the Pharmacist  
A video-based intervention in which patients 
are able to “ask” a pharmacist questions about 
their HIV prescriptions. 
Focus on the Fight  
Involves an activity that helps patients 
visualize the therapeutic effects of HIV 
medications. 
Helping Hand  
By playing the role of an adherence counselor 
to help other PLWHA overcome their barriers 
to adherence, patients learn strategies for 
dealing with their own adherence-related 
issues. 
HIV, Drugs, and Alcohol 
Discusses the effects of street drugs and 
alcohol on the body, street drug and alcohol 
interactions with ARV, and tips for staying 
healthy when using street drugs and/or 
alcohol. 
Journey through the Bloodstream  
An animated sequence that uses simple 
representations to explain T-Cells, CD-4 
count, HIV, viral load, how ARVs help fight 
HIV in the body, and drug resistance. 
Information Station  
Describes services locally available for 
PLWHA, including counseling and support 
groups, mental health services, substance 
abuse treatment, and housing assistance. 
Learning from a Missed Dose 
Patients are taught to assess the 
circumstances surrounding a missed dose and 
learn to identify, understand, and overcome 
their barriers to adherence. 
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Lipodystrophy  
Includes unscripted video accounts of four 
different personal experiences with 
lipodystrophy. The intervention also discusses 
possible causes and treatment options. 
Match-Up  
Patients create and print a personalized 
calendar on which ARV dose times are 
matched-up with recurring activities. 
Med Minders 
Describes tools and devices that can help 
patients take their medications on time, every 
time. 
The Misadventures of Skip Sisdose  
Uses humorous animation to provide tips for 
fitting ARV into one’s daily life, taking ARV 
when one’s routine changes, and taking ARV 
when others are around. 
My Meds  
A comprehensive resource that provides 
information about HIV medications, including 
dosing, side effects, drug interactions, and 
dietary restrictions for each medication. 
Patient-Provider Communication 
Addresses communication skills, with a focus 
on the doctor-patient relationship. Skills are 
presented through a series of video-based 
doctor-patient interactions. 
Positive Voices  
A video-based intervention in which 
participants can “ask” other PLWHA about 
their experiences with HIV and HIV 
medications. 
Side Effects Solutions  
Presents detailed information regarding side 
effects associated with HIV medications, and 
provides participants with tips and strategies 
for managing their side effects. 
Stress Management 
Patients learn about the nature of stress, 
particularly as it relates to living with HIV and 
ARV adherence. A variety of stress-reduction 
activities and strategies are provided. 
 
Information courtesy of LifeWindows Project Team 2006: Draft of results. 
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Table 10: Listing of Strategies Addressed in LifeWindows 
 
Learn more about your HIV medications, like how they’re supposed to be taken or 
what to do if you miss a dose. 
Learn how skipping your HIV medications from time to time can keep them from 
working for you and hurt your health. 
Learn more about how your HIV medications work in your body. 
Learn about the side effects of your HIV medications and ways to deal with them. 
Learn about ways to hide your HIV meds and to take them in private. 
Learn how to make your HIV medications part of your daily life and feel less 
frustrated about them. 
Learn ways to feel better about your HIV and your HIV medications. 
Work on ways to talk more effectively with your healthcare provider to get them to 
better understand your HIV medication needs. 
Learn how taking your HIV medications as prescribed can help you to live longer. 
Learn more about how HIV medications affect your health. 
Learn how HIV medications can affect the way you look and what you can do about 
it. 
Learn ways to get more support from others (such as friends, family, healthcare 
provider, pharmacist, etc.) for taking your HIV medications. 
Learn how to get the information you want about HIV treatment. 
Learn ways to get your medication refills on time. 
Learn things you can do to help you remember to take your HIV medications, even 
when you’re wrapped up in what you’re doing or your routine changes. 
Learn how to take pills that are too big, taste bad, or make you feel sick. 
Learn about taking HIV medications when using alcohol or street drugs. 
Learn how to deal with negative emotions and taking your HIV medications. 
Learn why you need to take your HIV medications as prescribed, even when you’re 
feeling healthy. 
Learn ways to take your HIV medications when you’re not feeling well. 
Learn how to identify what gets in the way of you taking your medications. 
Reward yourself for taking all of your HIV medications. 
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Table 11: Questions, Strategies, and Interventions used in LifeWindows 
 
Question Strategy Intervention 
Are you now taking a break from 
your HIV medications without 
having talked to your healthcare 
provider about it?  (Please click 
one.) Was not linked to a strategy Not Applicable 
As long as I am feeling healthy, 
missing my HIV medications from 
time to time is OK. 
Learn how skipping your HIV 
medications from time to time can 
keep them from working for you 
and hurt your health. 
Journey Through the 
Bloodstream, Doc 
Talk, Positive Voices 
During the past 4 weeks, how 
much did personal or emotional 
problems keep you from doing 
your usual work, school or other 
daily activities? Was not linked to a strategy Not Applicable 
During the past 4 weeks, how 
much did physical health 
problems limit your usual physical 
activities (such as walking or 
climbing stairs)? Was not linked to a strategy Not Applicable 
During the past 4 weeks, how 
much did your physical health or 
emotional problems limit your 
usual social activities with family 
or friends? Was not linked to a strategy Not Applicable 
During the past 4 weeks, how 
much difficulty did you have doing 
your daily work, both at home and 
away from home, because of 
your physical health? Was not linked to a strategy Not Applicable 
During the past 4 weeks, how 
much energy did you have? Was not linked to a strategy Not Applicable 
During the past 4 weeks, how 
much have you been bothered by 
emotional problems (such as 
feeling anxious, depressed, or 
irritable)? Was not linked to a strategy Not Applicable 
How hard is it for you to pay for 
your HIV medications each 
month? (Please click one.) 
Was not linked to a strategy Not Applicable 
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How hard or easy is it for you to 
get the support you need from 
others for taking your HIV 
medications (for example, from 
friends, family, doctor, or 
pharmacist)? 
Learn ways to get more support 
from others (such as friends, 
family, healthcare provider, 
pharmacist, etc.) for taking your 
HIV medications. 
Positive Voices. Doc 
Talk, Information 
Station, Patient-
Provider 
Communication, 
Felicia the 
Pharmacist, Helping 
Hand 
How hard or easy is it for you to 
get your HIV medication refills on 
time? 
Learn ways to get your medication 
refills on time. 
Felicia the 
Pharmacist. Helping 
Hand 
How hard or easy is it for you to 
make your HIV medications part 
of your daily life? 
Learn how to make your HIV 
medications part of your daily life 
and feel less frustrated about 
them. 
Match-Up, Positive 
Voices, Doc Talk, 
Focus on the Fight, 
Stress Management, 
Med Minders, 
Misadventures of 
Skip Sisdose, Battle 
for Health 
How hard or easy is it for you to 
manage the side effects of your 
HIV medications? 
Learn about the side effects of 
your HIV medications and ways to 
deal with them. 
Side Effects 
Solutions, My Meds, 
Felicia the 
Pharmacist, Doc 
Talk, Positive Voices, 
Lipodystrophy, 
Helping Hand 
How hard or easy is it for you to 
remember to take your HIV 
medications? 
Learn things you can do to help 
you remember to take your HIV 
medications, even when you’re 
wrapped up in what you’re doing 
or your routine changes. 
Med Minders, Match-
Up, Battle for Health, 
Positive Voices, 
Helping Hand, 
Misadventures of 
Skip Sisdose 
How hard or easy is it for you to 
stay informed about HIV 
treatment? 
Learn how to get the information 
you want about HIV treatment. 
Patient-Provider 
Communication, Doc 
Talk, Felicia the 
Pharmacist, 
Information Station 
How hard or easy is it for you to 
take your HIV medications 
because the pills are hard to 
swallow, taste bad, or make you 
sick to your stomach? 
Learn how to take pills that are too 
big, taste bad, or make you feel 
sick. 
Bill the Pill, Side 
Effect Solutions, Doc 
Talk, Felicia the 
Pharmacist, Battle for 
Health 
How hard or easy is it for you to 
take your HIV medications when 
you are wrapped up in what you 
are doing? 
Learn things you can do to help 
you remember to take your HIV 
medications, even when you’re 
wrapped up in what you’re doing 
or your routine changes. 
Med Minders, Match-
Up, Battle for Health, 
Positive Voices, 
Helping Hand, 
Misadventures of 
Skip Sisdose 
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How hard or easy is it for you to 
take your HIV medications when 
you do not feel good emotionally 
(for example, when you are 
depressed, sad, angry, or 
stressed out)? 
Learn how to deal with negative 
emotions and taking your HIV 
medications. 
Stress Management, 
Positive Voices, 
Information Station, 
Helping Hand 
How hard or easy is it for you to 
take your HIV medications when 
you do NOT feel good physically? 
Learn ways to take your HIV 
medications when you’re not 
feeling well. 
Side Effects 
Solutions, Bill the Pill, 
Doc Talk, Positive 
Voices, Helping 
Hand, Focus on the 
Fight 
How hard or easy is it for you to 
take your HIV medications when 
you feel good physically and don’t 
have any symptoms of your HIV 
disease? 
Learn why you need to take your 
HIV medications as prescribed, 
even when you’re feeling healthy. 
Positive Voices, Doc 
Talk, Journey 
Through the 
Bloodstream 
How hard or easy is it for you to 
take your HIV medications when 
your usual routine changes (for 
example, when you travel or 
when you go out with your 
friends)? 
Learn things you can do to help 
you remember to take your HIV 
medications, even when you’re 
wrapped up in what you’re doing 
or your routine changes. 
Med Minders, Match-
Up, Battle for Health, 
Positive Voices, 
Helping Hand, 
Misadventures of 
Skip Sisdose 
How hard or easy is it for you to 
talk to your healthcare provider 
about your HIV medications? 
Work on ways to talk more 
effectively with your healthcare 
provider to get them to better 
understand your HIV medication 
needs. 
Patient-Provider 
Communication, Doc 
Talk, Helping Hand 
How much bodily pain have you 
had during the past 4 weeks? Was not linked to a strategy Not Applicable 
How often do you use a pillbox to 
help keep track of your HIV 
medications? (Please click one.) Was not linked to a strategy Not Applicable 
I am worried that other people 
might realize that I am HIV+ if 
they see me taking my HIV 
medications. 
Learn about ways to hide your HIV 
meds and to take them in private. 
Med Minders, 
Misadventures of 
Skip Sisdose, Felicia 
the Pharmacist, Doc 
Talk, Positive Voices, 
Battle for Health, 
Helping Hand 
I am worried that the HIV 
medications I have been 
prescribed will hurt my health. 
Learn more about how HIV 
medications affect your health. 
Side Effects 
Solutions, Doc Talk, 
Positive Voices, My 
Meds, Lipodystrophy, 
Journey Through the 
Bloodstream, Helping 
Hand 
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I believe that if I take my HIV 
medications as prescribed, I will 
live longer. 
Learn how taking your HIV 
medications as prescribed can 
help you to live longer. 
Journey Through the 
Bloodstream, Doc 
Talk, Positive Voices, 
Battle for Health, 
Helping Hand 
I don’t like taking my HIV 
medications because they remind 
me that I am HIV+. 
Learn ways to feel better about 
your HIV and your HIV 
medications. 
Focus on the Fight, 
Positive Voices, Doc 
Talk, Stress 
Management, 
Information Station, 
Helping Hand 
I feel that my healthcare provider 
takes my needs into account 
when making recommendations 
about which HIV medications to 
take. 
Work on ways to talk more 
effectively with your healthcare 
provider to get them to better 
understand your HIV medication 
needs. 
Patient-Provider 
Communication, Doc 
Talk, Helping Hand 
I get frustrated taking my HIV 
medications because I have to 
plan my life around them. 
Learn how to make your HIV 
medications part of your daily life 
and feel less frustrated about 
them. 
Match-Up, Positive 
Voices, Doc Talk, 
Focus on the Fight, 
Stress Management, 
Med Minders, 
Misadventures of 
Skip Sisdose, Battle 
for Health 
I know how each of my current 
HIV medications is supposed to 
be taken (for example whether or 
not my current medications can 
be taken with food, herbal 
supplements, or other 
prescription medications). 
Learn more about your HIV 
medications, like how they’re 
supposed to be taken or what to 
do if you miss a dose. 
Felicia the 
Pharmacist, My Meds 
I know how my HIV medications 
interact with alcohol and street 
drugs. 
Learn about taking HIV 
medications when using alcohol or 
street drugs. 
HIV, Drugs, and 
Alcohol, My Meds, 
Doc Talk, Positive 
Voices 
I know what the possible side 
effects of each of my HIV 
medications are. 
Learn about the side effects of 
your HIV medications and ways to 
deal with them. 
Side Effects 
Solutions, My Meds, 
Felicia the 
Pharmacist, Doc 
Talk, Positive Voices, 
Lipodystrophy, 
Helping Hand 
I know what to do if I miss a dose 
of any of my HIV medications (for 
example, whether or not to take 
the pill(s) later). 
Learn more about your HIV 
medications, like how they’re 
supposed to be taken or what to 
do if you miss a dose. 
Felicia the 
Pharmacist, My Meds 
I understand how each of my HIV 
medications works in my body to 
fight HIV. 
Learn more about how your HIV 
medications work in your body. 
Journey Through the 
Bloodstream, Doc 
Talk, Positive Voices 
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If I don’t take my HIV medications 
as prescribed, these kinds of 
medications may not work for me 
in the future. 
Learn how skipping your HIV 
medications from time to time can 
keep them from working for you 
and hurt your health. 
Journey Through the 
Bloodstream, Doc 
Talk, Positive Voices 
It frustrates me to think that I will 
have to take these HIV 
medications every day for the rest 
of my life. 
Learn ways to feel better about 
your HIV and your HIV 
medications. 
Focus on the Fight, 
Positive Voices, Doc 
Talk, Stress 
Management, 
Information Station, 
Helping Hand 
It upsets me that the HIV 
medications I have been 
prescribed can affect the way I 
look. 
Learn how HIV medications can 
affect the way you look and what 
you can do about it. 
Lipodystrophy. Doc 
Talk, Side Effect 
Solutions 
It upsets me that the HIV 
medications I have been 
prescribed can cause side 
effects. 
Learn about the side effects of 
your HIV medications and ways to 
deal with them. 
Side Effects 
Solutions, My Meds, 
Felicia the 
Pharmacist, Doc 
Talk, Positive Voices, 
Lipodystrophy, 
Helping Hand 
Most people who are important to 
me who know I’m HIV positive 
support me in taking my HIV 
medications. 
Learn ways to get more support 
from others (such as friends, 
family, healthcare provider, 
pharmacist, etc.) for taking your 
HIV medications. 
Positive Voices. Doc 
Talk, Information 
Station, Patient-
Provider 
Communication, 
Felicia the 
Pharmacist, Helping 
Hand 
My healthcare provider doesn’t 
give me enough support when it 
comes to taking my medications 
as prescribed. 
Learn ways to get more support 
from others (such as friends, 
family, healthcare provider, 
pharmacist, etc.) for taking your 
HIV medications. 
Positive Voices. Doc 
Talk, Information 
Station, Patient-
Provider 
Communication, 
Felicia the 
Pharmacist, Helping 
Hand 
Overall, how would you rate your 
health during the past 4 weeks? Was not linked to a strategy Not Applicable 
Skipping a few of my HIV 
medications from time to time 
would not really hurt my health. 
Learn how skipping your HIV 
medications from time to time can 
keep them from working for you 
and hurt your health. 
Journey Through the 
Bloodstream, Doc 
Talk, Positive Voices 
There are times when it is hard 
for me to take my HIV 
medications when I drink alcohol 
or use street drugs. 
Learn about taking HIV 
medications when using alcohol or 
street drugs. 
HIV, Drugs, and 
Alcohol, My Meds, 
Doc Talk, Positive 
Voices 
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When was the last time you 
injected or “shot up” street drugs 
(such as heroin or cocaine)? Was not linked to a strategy Not Applicable 
      
During the Self-Report: if the 
Patient had Less than 100% 
adherence 
Learn how to identify what gets in 
the way of you taking your 
medications. 
Learning From a 
Missed Dose 
During the Self-Report: If the 
Patient had 100% adherent 
Reward yourself for taking all of 
your HIV medications. Celebrate Success 
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Table 12: Barriers Addressed in LifeWindows  
 
Being in a state of poor health  
Changes in one’s daily routine 
Difficulty in engaging in social activities due to health problems 
Difficulty in gathering information 
difficulty in identifying barriers to adherence 
Difficulty in making medications a part of daily life 
Difficulty in managing the side effects to medications 
Difficulty in performance of daily work due to physical health problems 
Difficulty in refilling prescriptions 
Difficulty in taking medications when not feeling good physically  
Experiencing and dealing bodily pain 
Experiencing bodily pain 
Fear of a medications’ side effects 
Fear of side effects that affect physical appearance 
Fear that others may find out about HIV status if medications are taken in public  
Financial Issues 
Forgetting to take medications 
Frustration about having to take medications 
Frustration in having to plan life around medications 
Frustration that HIV medications must be taken every day for life 
Issues dealing with privacy and disclosure of HIV status  
Lack of energy 
Lack of knowledge about ARV therapy in relation of missing a dose 
Lack of knowledge about ARV therapy in relation to side effects 
Lack of knowledge about HIV and ARV therapy 
Lack of social support structures 
Negative emotions towards HIV and/or ARV therapy 
Negative feelings towards medications because side effects can affect the 
physical appearance 
Not acknowledging one's accomplishments 
Not adhering to ARV therapy 
Not feeling good emotionally 
Not feeling good emotionally 
Not using a pillbox or other reminder device 
Physical health problems limit ability to perform daily functions 
Physical health problems limit ability to take medications 
Poor patient-provider communication 
Problem taking pills 
 
 
 
 
